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found in the regions vulnerable to inclusion formation. Finally, given the lack of correlation between
Lamp-2a levels and CMA activity across brain regions, we explored the possibility that additional proteins
may participate in the direct lysosomal uptake and degradation of substrates. These data provide
evidence of regional insufficiencies in lysosomal function that underlie the selective initiation of αsynuclein aggregation.
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ABSTRACT
REGIONAL LYSOSOMAL MALFUNCTION UNDERLIES THE SELECTIVITY
OF
α-SYNUCLEIN NEURODEGENERATION
Kristen Ashley Malkus
Harry Ischiropoulos, Ph.D.

Dysfunction of protein homoeostasis has been implicated in the pathogenesis of a diverse
array of neurodegenerative disorders.

However, each neurodegenerative disease is

characterized by the accumulation of particular proteins in select regions of the brain. It
remains unclear how dysfunction of a ubiquitous protein degradation pathway results in
distinct pathologies. α-Synuclein is a protein whose aggregation and oligomerization has
been implicated in several diseases, including Parkinson’s disease (PD). Herein, we
investigated regionally selective alterations in α-synuclein degradation to decipher
potential mechanisms underlying its role in disease. Chaperone mediated autophagy
(CMA), a selective route of direct lysosomal degradation, participates in the turnover of
α-synuclein. In a mouse model of synucleinopathy, we show that the levels of the CMA
receptor Lamp-2a are dynamically upregulated upon the development of motor symptoms
in the regions that form the most prominent inclusions. However, increased levels of
Lamp-2a were unable to induce greater lysosomal substrate binding and degradation.
The regions of the brain that develop the most prominent inclusions were found to have
iii

decreased CMA activity compared to the regions of the brain that develop minimal
inclusions. Additionally, markers of lysosome and autophagosome levels were decreased
in the inclusion-forming regions. Therefore, multiple lysosomal deficiencies potentially
contribute to the selective aggregation of α-synuclein. However, during such conditions
of impaired degradation, many substrates are presumably affected. Therefore, we next
investigated potential factors that mediate the vulnerability of α-synuclein to aggregation.
While no defects were detected in the ability of α-synuclein to be recognized as a CMA
substrate or unfolded for lysosomal uptake, altered levels of proteins involved in lipid
metabolism were found in the regions vulnerable to inclusion formation. Finally, given
the lack of correlation between Lamp-2a levels and CMA activity across brain regions,
we explored the possibility that additional proteins may participate in the direct
lysosomal uptake and degradation of substrates. These data provide evidence of regional
insufficiencies in lysosomal function that underlie the selective initiation of α-synuclein
aggregation.
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CHAPTER 1
Introduction
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1.1 Introduction
Protein aggregation is a hallmark of a diverse array of late-onset
neurodegenerative disorders.

Despite this unifying trademark, these diseases, which

include Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease
(HD), are each characterized by inclusions composed of distinct proteins in selectively
disparate regions of the brain. The shared presence of amyoidogenic inclusions implies
that there is a common underlying problem with protein homeostasis among these
diseases. However, the unique pathology of each disease suggests that different causative
factors are involved.
Both histological and biochemical analysis of diseased human brain has revealed
the presence of these protein aggregates. These aggregates are composed of fibrils of
protein structured in stacks of antiparallel β-pleated sheets called amyloid.

These

aggregates are insoluble in non-ionic detergents, are typically immunoreactive for
ubiquitin, and are able to intercolate dyes such as Thioflavin-T and Congo Red between
the strands of β-pleated sheets.
While the precise mechanism underlying the transformation of a protein to
amyloid remains unknown, it is likely that a disruption of protein homeostasis plays a
role. Following protein translation, a protein transitions into the most thermodynamically
stable conformation it is able to form. If this structure is misfolded, a variety of cellular
processes are recruited to assist the protein. Molecular chaperones attempt to aid the
protein in refolding to its proper conformation, and if this re-folding fails, the protein is
degraded. Failure of any part of this system allows the accumulation of misfolded
proteins and energetically favorable interactions between these proteins, such as through
2

exposed hydrophobic residues, promote protein aggregation. Consequently, the role of
molecular chaperones and protein degradation machinery in neurodegenerative diseases
has been the subject of much research. However, it is unclear how dysfunction of protein
homeostasis occurs in a selective way that leads to the unique vulnerability of certain
proteins in distinct brain regions to aggregate and ultimately induce neurodegeneration.

1.2 Parkinson’s disease
First described by Dr. James Parkinson in 1817, Parkinson’s disease (PD) is
characterized clinically as difficulty initiating movements, resting tremor, postural
instability, and rigidity (Hoehn and Yahr, 1967).

The second most prevalent

neurodegenerative disorder, PD is estimated to affect 1-2% of the U.S. population over
the age of 60 (de Lau and Breteler, 2006; Thomas and Beal, 2007). Age is the greatest
risk factor for PD. Therefore, while the current estimate of affected individuals is
approximately 1.5million people within the U.S., this number is expected to increase as
the average age of the population continues to climb (Thomas and Beal, 2007).
Pathologically, two predominant features characterize PD. The first is the loss of
selective neuronal populations.

The most extensive degeneration occurs in the

dopaminergic neurons of the substantia nigra pars compacta and is responsible for the
motor deficits described clinically (Forno, 1996). However, other brain regions also
experience cell death, including the basal nucleus of Meynert and brainstem regions such
as the locus coeruleus and the raphe nuclei (Mayeau et al., 1984; Whitehouse et al.,
1983). The second pathological hallmark of PD is the presence of intracellular protein
inclusions known as Lewy bodies, which are, in part, made of fibrillar structures. Lewy
3

bodies derive their name from the German neurologist Fritz Heinrich Lewy who first
described their abundance in post-mortem PD tissue (Lewy, 1912).

Pathology is

presumed to originate from the lower brainstem regions and progress to include other
areas such as the locus coeruleus, raphe nucleus, substantia nigra, amygdala, and
neocortex (Braak et al., 2006) (Figure 1-1). The appearance of Lewy body inclusions in
the regions that develop neuron loss initially suggested that protein aggregation directly
induced neural dysfunction. However, a causative relationship has not been established,
and alternate hypotheses have been proposed to explain the correlative findings,
including possible toxicity of the oligomeric intermediates that are formed before
inclusions

are

Figure 1-1
Schematic of the
progression of Lewy body pathology
in Parkinson’s Disease. Inclusion
formation is believed to originate in the
brainstem and anterior olfactory areas
and then progress through the
remainder of the brain while increasing
in severity (top).
The systematic
spread of inclusions through brain
regions allows pathology to be divided
into six stages of disease (below).
Once inclusions have progressed to the
Substantia Nigra, the motor symptoms
associated with PD become apparent.
Darker shades of grey indicate
increased abundance of Lewy bodies.

formed (Gosavi
et

al.,

Kayed
2003;
and

2002;
et

al.,

Volles
Lansbury,

2003; Tsika et
al.,

2011;

Winner et al.,

Figure is from Braak et al., Movement
Disorders (21), 2006

2011).

While several different treatment strategies exist to help patients with the
management of PD symptoms, there is currently no cure for PD. One of the major
challenges in designing an effective therapy for PD is that, despite decades of promising
research in the field, the precise molecular mechanisms underlying the disease remain
4

unknown.

While the majority of PD cases are sporadic, rare instances of familial

inheritance of the disease have helped to provide insight into potential causes. Currently
fifteen genetic loci, denoted PARK1–15, have been associated with PD. From these loci,
at least six genes have been established as a causative factor of familial PD: α-synuclein
(PARK1/4), parkin (PARK2), PINK1(PARK6), DJ-1 (PARK7), LRRK2 (PARK8), and
ATP13A2 (PARK9) (Lesage and Brice, 2009; Gasser, 2009; Polymeropoulos et al.,
1997; Kitada et al., 1998; Bonifati et al., 2003; Valente et al., 2004; Paisan-Ruiz et al.,
2004; Zimprich et al., 2004; Ramirez et al., 2006). The first of these genetic links came
following the description of a large Italian kindred (Contursi) and three small Greek
families with a dominantly inherited, early-onset, severe form of PD (Golbe et al., 1996).
Genetic analysis of the families revealed a single nucleotide missense mutation (G209A)
in the SNCA gene which led to the amino acid substitution of a threonine for an alanine
at position 53 of the α-synuclein protein (Polymeropoulos et al., 1996; Polymeropoulos et
al., 1997). Shortly following this discovery, it was found that antibodies raised against αsynuclein demonstrated strong immunoreactivity against the hallmark Lewy body
inclusions and Lewy neurites in brain tissue from patients with sporadic PD (Spillantini
et al., 1997, 1998a,b; Baba et al., 1998). Subsequently, two other point mutations in αsynuclein have been associated with a genetically inherited form of PD, as has
duplication or triplication of the gene, with triplication producing an early onset, severe
form of the disease (Krüger et al., 1998; Chartier-Harlin et al., 2004; Zarranz et al., 2004;
Farrer et al., 2004; Ibanez et al., 2004; Singleton et al., 2003). This evidence has
suggested a key role for α-synuclein in PD neurodegeneration.

5

1.3 α-Synuclein as a pathogenic protein
1.3.1 Synucleinopathies
Prior to the association of α-synuclein with PD pathology, a region of the protein
was identified as a component within the amyloid plaques of Alzheimer’s disease and
was consequently deemed the “Non-Aβ component of Alzheimer’s disease amyloid
plaque” (NACP) (Ueda et al., 1993). While it has been debated that this finding was due
to contamination from Lewy bodies and Lewy neurites (Bayer et al., 1999), it
nevertheless supports the association of this protein with aggregate formation and
neurodegeneration.

In addition to PD, α-synuclein pathology is found throughout

several other diseases, collectively referred to as synucleinopathies.

These

synucleinopathies, which include dementia with Lewy bodies (DLB), Lewy body variant
of Alzheimer’s disease (LBVAD), and multiple system atrophy (MSA) are unified by the
presence of insoluble filamentous aggregates of α-synuclein, but are delineated by a
disparate distribution of these inclusions throughout the brain. In DLB, patients present
with progressive dementia accompanied by bradykinesia. α-Synuclein positive Lewy
bodies and Lewy neurites are found primarily in the cerebral cortex, substantia nigra, and
striatum (Kosaka, 1978; McKeith et al., 1996). The closely related LBVAD has a similar
presentation, but in this disease the cortical Lewy body inclusions are accompanied by
the presence of neurofibrillary tangles and amyloid plaques (Hansen et al., 1990; Samuel
et al., 1996). In contrast to the primarily neuronal aggregation of α-synuclein seen in PD,
DLB, and LBVAD, the α-synuclein aggregates in MSA are found mainly in
oligodendrocytes (Gai et al., 2003; Duda et al., 2000; Tu et al., 1998; Papp et al., 1989).
Referred to as glial cytoplasmic inclusions, these α-synuclein aggregates are
6

predominantly located in the neocortex, hippocampus, basal ganglia, substantia nigra,
spinal cord, medulla, and cerebellum (Arima et al., 1992; Duda et al., 2000). Patients
with MSA exhibit motor impairments, such as bradykinesia, postural ridigity and
instability, and gait ataxia, as well as autonomic problems such as impotence, urinary
incontinence, and orthostatic hypotension, and occasionally mild cognitive impairment
(Wenning et al., 1997).

This family of neurodegenerative diseases suggests an

underlying toxic role for α-synuclein. However, it remains unknown how this protein is
able to induce cell death as well as how it exerts a regional selectivity for its effects in
different diseases.
1.3.2. Properties of α-Synuclein
α-Synuclein is a 140 amino acid cytoplasmic protein that is concentrated in the
presynaptic terminals of the brain (Jakes et al., 1994; Maroteaux et al., 1988; Iwai et al.,
1995). While it is most highly expressed in the neurons of the central nervous system, αsynuclein also is present in many other tissues of the body (Ueda et al., 1993; Iwai et al.,
1995). The precise function of α-synuclein remains unclear; however, evidence suggests
that it plays a role in the recruitment of neurotransmitter vesicles from the reserve
vesicular pool, and may additionally have a chaperone-like activity (Chandra et al., 2005;
Maroteaux and Scheller, 1991; Murphy et al., 2000; Ostrerova et al., 1999; Souza et al.,
2000). α-Synuclein knockout mice are viable and develop normally (Abeliovich et al.,
2000).

However, these mice exhibit impaired stimulus dependent neurotransmitter

release (Abeliovich et al., 2000; Cabin et al., 2002). Interestingly, these knockout mice
are also resistant to the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin
that is able to induce selective degeneration of dopaminergic neurons and α-synuclein
7

positive inclusions (Dauer et al., 2002; Klivenyi et al., 2006; Drolet et al., 2004, Forno et
al., 1988; Kowall et al., 2000; Forno et al., 1986; Moratalla et al., 1992).
α-Synuclein has been described as being natively unfolded in solution, due to
investigations using gel filtration, sedimentation analysis, CD, FTIR, and NMR analyses
of the purified protein (Weinreb et al., 1996; Eliezer et al., 2001). This natively unfolded
structure has been attributed to the acidic C-terminus of the protein. However, the Nterminus of the protein contains a series of amphipathic KTKEGV imperfect repeats
which resemble the lipid binding domain of apolipoproteins and allow the protein to
adopt an α-helical conformation in the presence of lipids or SDS (George et al., 1995;
Davidson et al., 1998; Conway et al., 1998; Jo et al., 2000; Eliezer et al., 2001). Residues
61-95 of α-synuclein are hydrophobic and form the aggregate-prone region of the protein.
Specifically, residues 71-82 have been shown to be crucial for the formation of
amyloidogenic β-pleated sheet fibrils (Giasson et al., 2001)
Despite being endogenously unfolded, α-synuclein has been shown readily
fibrillize in vitro (Conway et al., 1998; Conway et al., 2000c). This polymerization
progresses in a nucleation-dependent fashion with oligomeric species forming as
intermediates following an initial lag phase (Wood et al., 1999; Conway et al., 2000b;
Uversky et al., JBC, 2001). While the initial investigations focused on the role of the
fibrillar aggregates as the potentially toxic species in disease, other investigations indicate
that the oligomeric intermediates may, in fact, be more detrimental (Gosavi et al., 2002;
Kayed et al., 2003; Volles and Lansbury, 2003; Winner et al., 2011). Recently, Tsika et
al. (2010) found that in a mouse model of α-synucleinopathy, the oligomers that form in
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the inclusion-bearing regions of the brain are biochemically distinct from the oligomers
found in the regions relatively spared from inclusion formation.
1.3.3. The effect of α-synuclein modifications on aggregation
In disease, the kinetics of α-synuclein conformers is shifted to promote the
formation of oligmers and ultimately aggregates.

Therefore, different factors that

promote this shift towards aggregation have been widely explored. α-Synuclein point
mutations that are associated with familial forms of PD have been found to accelerate
oligomerization in vitro (Conway et al., 2000a,b; Greenbaum et al., 2005). Additionally,
the A53T mutation, and, to a lesser extent, the E46K mutation, accelerate fibrillization of
the protein into amyloidogenic fibrils (Nahri et al., 1999; Conway et al., 1998; Giasson et
al., 1999; Greenbaum et al., 2005)
In vivo, the role of α-synuclein mutations is unclear. In cells, the A53T mutation
has been found to increase the half-life of α-synculein (Li W et al., 2004). Expression of
A53T α-synuclein in differentiated cells results in the formation of insoluble aggregates
and increased cell toxicity compared to expression of wild type α-synuclein (Mazzulli et
al., 2006).

Additionally, A53T α-synuclein has been found to make cells more

susceptible to a variety of insults including oxidative stress, MPP+, protein kinase
inhibition, and proteasome inhibition (Lee M et al., 2001). However, Hashimoto et al.
(2002) conversely found that α-synuclein expression can be protective against oxidative
stress in cells.
In flies, expression of human α-synuclein results in degeneration of dopaminergic
neurons, motor dysfunction, and inclusion formation. However, the A53T or A30P
pathogenic mutations do not exacerbate any of these phenotypes (Feany and Bender,
9

2000). In mice, expression of A53T human α-synuclein driven by the Thy-1 promoter
induces non-amyloidogenic accumulation of α-synuclein, but wild-type human αsynuclein has a similar effect (van der Putten et al., 2000). Thy-1 driven expression of
A30P α-synuclein does appear to induce the formation of fibrillar α-synuclein inclusions
(Kahle PJ, 2001). In mice expressing α-synuclein driven by the murine prion promoter,
expression of A53T α-synuclein induces a motor phenotype and α-synuclein inclusions,
while wild-type α-synuclein expression does not (Giasson et al., 2002; Lee MK et al.,
2002).

Expression of A30P α-synuclein driven by this promoter did not induce

phenotypic changes or α-synuclein aggregation in one strain, but did induce motor
dysfunction and decreased lifespan in a different strain (Lee MK et al., 2002; Gallardo et
al., 2008). Consequently, the precise impact that these mutations found in familial cases
of PD have on α-synuclein aggregation and cell toxicity is unclear.
Additionally, examination of the pathogenic mutations of α-synuclein does not
explain the role of the protein in sporadic PD. Additional investigations have focused on
other modifications of the wild-type protein. Examination of immunoreactivity of Lewy
bodies from postmortem tissue has revealed extensive modification of α-synuclein by
phosphorylation at Serine 129 (Fujiwara et al., 2002; Anderson et al., 2006). Preventing
this modification by mutation of the serine to an alanine decreases toxicity in cells and in
vivo (Chen and Feany, 2005; Smith WW et al., 2005).

The precise role of this

modification on α-synuclein aggregation remains controversial and is still being
investigated (Chen and Feany, 2005; Anderson et al., 2006; Paleologou et al., 2008;
Fujiwara et al., 2002; Hasegawa et al., 2002).

10

α-Synuclein nitrated on tyrosine residues has been identified in the detergentinsoluble fraction of the brains of PD patients, suggesting that this modification may
induce the aggregation of this protein or that aggregated forms of the protein are
selectively modified by nitrating oxidants (Giasson et al., 2000). MPTP, rotenone, and
paraquat are neurotoxins shown to induce oxidative stress. In cell, mouse, and nonhuman primate models, treatment with MPTP has been shown to increase oxidative
modifications and aggregation of α-synuclein (Kowall et al., 2000;Vila et al., 2000;
Gomez-Santos et al., 2002). Treatment of cells or rats with rotenone and mice with
paraquat similarly increased α-synuclein aggregation and inclusion formation and cellular
dysfunction (Manning-Bog et al., 2002; Betarbet et al., 2000; Sherer et al., 2002).
Collectively, these findings led to biochemical examination of the effect of oxidative or
nitrative modification on α-synuclein. Fibrillar α-syncuclein aggregates with a
perinuclear localization were formed in cells expressing α-syncuclein upon kinetically
controlled exposure to nitric oxide and superoxide (Paxinou et al., 2001). Nitration of αsynuclein monomers and dimers is able to accelerate the rate of fibril formation through
the recruitment of non-nitrated α-synuclein, but nitration of oligomers inhibits fibril
formation (Hodara et al., 2004; Krishnan et al., 2003; Yamin et al., 2003). In addition to
nitration, exposure of α-synuclein to nitrating oxidants and oxidative modifications also
results in cross linking and the formation of stable fibrils (Souza et al., 2000; Norris et al.,
2003; Paik et al., 2000). (The previous paragraph is taken from Malkus et al., 2009).
Due to the regional specificity of pathology in PD patients, the effect of dopamine
on α-synuclein has also been investigated. Dopamine is able to interact with α-synuclein
and inhibit the formation of α-synuclein fibrils by arresting aggregation at the oligomeric
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stage (Conway et al., 2001). Dopamine oxidation is essential for this kinetic arrest of αsynuclein oligomers (Norris et al., 2005). Examination of putative amino acid targets in
α-synuclein revealed that the interaction of oxidized dopamine with α-synuclein is
directed, not towards a single amino acid, but rather five amino acid residues: tyrosineglutamate-methionine-proline-serine (YEMPS) in position 125–129 in the C-terminus of
the protein (Norris et al., 2005; Mazzulli et al., 2007). Recent studies have confirmed
these findings and also indicated that the glutamate 83 residue also participates in
stabilizing the interaction of oxidized dopamine with the YEMPS region (Herrera et al.,
2008). The in vitro data has been confirmed in cellular model systems that express A53T
α-synuclein or A53T α-synuclein with all 5 amino acids 125–129 mutated, establishing
the importance of this C terminal region in the stabilization of α-synuclein oligomers in
the presence of oxidized dopamine (Mazzulli et al., 2006, 2007). The decrease in
catecholamine levels that has been described as an early event in PD pathogenesis
(Nagatsu, 1990) may then allow the formation of insoluble α-synuclein aggregates later
in disease (Mazzulli et al., 2006). (The previous paragraph is taken from Malkus et al.,
2009).
While investigation of these various modifications have provided great insight
into the biochemistry of α-synuclein aggregation, no direct causative relationship for the
endogenous pathology that occurs in vivo has been established. Due to the importance of
cellular homeostasis in aggregate formation, one possibility is that reduced clearance of
α-synuclein increases the toxic effects of these modifications. Additionally, given recent
evidence that aggregated α-synuclein can be transmitted from one neuron to another, it is
possible that impaired degradation of α-synuclein in one neuron may induce a cascade of
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aggregation and neurodegeneration in surrounding neurons (Kordower et al., 2008;
Desplats et al., 2009; Luk et al., 2009).

This has potential implications for the

progression of the disease and the spread of pathology through various brain regions.
One factor shifting α-synuclein kinetics may have widespread effects.

1.4 Protein Degradation Systems
1.4.1 Protein homeostasis and disease
The presence of protein inclusions in synucleinopathies suggests that altered
protein homoestasis may contribute to disease. Indeed, protein levels in part facilitate the
aggregation of α-syn, since α-syn exhibits a concentration-dependent aggregation in vitro,
and duplication or triplication of the gene encoding α-syn leads has been associated with
a genetically inherited form of PD (Conway et al., 1998; Giasson et al., 1999; ChartierHarlin et al., 2004).

Consequently, much research has focused on the molecular

mechanisms by which neurons
control steady state levels of α-syn.
Two

major

pathways

are

responsible for the clearance of
cellular proteins: the ubiquitinproteasome system (UPS) and the
autophagy-lysosome

pathway

(Rubinsztein et al., 2006; Ross et
al., 2004; Wong and Cuervo, 2010)

Figure 1-2. Protein degradation pathways. Cellular
proteins are degraded primarily by either the UPS (1) or
one of the 3 autophagic pathways: macroautophagy (2),
microautophagy (3), or chaperone mediated autophagy
(CMA) (4).
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(Figure 1-2). While the both the UPS and autophagy have been implicated as potential
contributors to neurodegeneration, their precise involvement is controversial and unclear.

1.4.2 The Ubiquitin Proteasome System
The UPS is the principal mechanism of degradation for short-lived proteins and
proteins that are misfolded in the endoplasmic reticulum. UPS substrates are selectively
targeted for degradation by the 20S or 26S proteasome complex after the conjugation of a
polyubiquitin tag through a three-step enzymatic cascade. Upon recruitment to the
proteasome, the substrates must be unfolded to pass through the narrow barrel of the
proteasome where they are degraded (Ross, 2004; Rubinsztein, 2006). The consistent
observation that antibodies against ubiquitin label some of the human and rodent protein
inclusions suggests that failure of the UPS may contribute to neurodegeneration (Lowe et
al., 1988). It has been suggested that α-synuclein may initiate UPS inhibition, as it has
been shown to disrupt the proteasome in vitro, an effect that is enhanced by the
pathogenic α-synuclein mutations (Stefanis et al., 2001; Tanaka et al., 2001; Petrucelli et
al., 2002; Snyder et al., 2003). The mechanisms underlying this inhibition are not fully
understood, though possibilities include binding of α-synuclein to a subunit of the
proteasome, blockage of the proteasome by aggregated proteins, or potentially an
unknown downstream mechanism. (The previous paragraph is taken from Malkus et al.,
2009).
Additionally, UPS inhibition caused by factors other than α-synuclein may
nevertheless have an impact on the homeostasis and toxicity of α-synuclein.

UPS

inhibition has yielded evidence of cell death and protein aggregation in several cellular
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model systems as well as rodent models (Bennett, 1999; Stefanis et al., 2001; Snyder,
2003; McNaught et al., 2004; Zeng et al., 2006; Schapira et al., 2006). However, other
studies have yielded conflicting results (Ancolio et al., 2000; Paxinou et al., 2001;
Manning-Bog et al., 2006; Bove et al., 2006; Kordower et al., 2006), leaving the role of
the UPS in α-synuclein neurodegeneration not entirely resolved. These variable results
suggest that other factors, including other protein degradation pathways such as
autophagy, may contribute to cellular viability.
1.4.3 Autophagy
The other primary pathway for protein degradation in the cell is through
autophagy. While the ultimate result of autophagy is always the delivery of proteins or
organelles to the lysosome for degradation, there are several different routes by which
this can be accomplished. Macroautophagy is typically regarded as a non-selective
method of bulk degradation whose activity is upregulated in response to stress. However,
recently selective forms of macroautophagy have become apparent. For example, in
mitophagy, the loss of membrane potential in select mitochondria leads to their
recognition, uptake, and degradation by macroautophagy components (reviewed in
Vives-Bauza and Przedborski, 2011). Additionally, proteins with ubiquitin modifications
may be selectively targeted for autophagic degradation following recognition by specific
ubiquitin receptors that target the proteins to autophagosomes (Reviewed in Kirkin et al.,
2009).
Macroautophagy was first implicated in neurodegeneration after it was noted that
autophagic structures were present in affected brain regions of patients with
neurodegenerative diseases, including PD (Anglade et al., 1997; Nixon et al., 2005; Sapp
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et al., 1997; Cataldo et al., 1996). Initial hypotheses speculated that these autophagic
vacuoles were evidence of neurons "eating themselves to death" (Anglade et al., 1997).
This was based on previous observations that autophagic mechanisms can participate in
induction of non-apoptotic cell death cascades (Hornung et al., 1989; Xue et al., 1999;
Yue et al., 2002; Borsello et al., 2003; Yu et al., 2003; Yu et al., 2004; Shimizu et al.,
2004). However, recent evidence has shown that, particularly within the context of
neurodegeneration, macroautophagy may instead serve as a protective process by which
cells attempt to clear misfolded proteins and damaged organelles. Independently
generated data has revealed the neuroprotective role of macroautophagy through
manipulation of either Atg7 or Atg5 – two different proteins essential for autophagy.
Conditionally knocking out either of these genes in the central nervous system of mice
leads to severe neurodegeneration and formation of protein inclusions, accompanied by
motor dysfunction and early death (Hara et al., 2006; Komatsu et al., 2006). In cells,
inhibition of macroautophagy at the stage of autophagosome formation by 3methyladenine (3-MA), at the stage of autophagosome-lysosome fusion by Bafilomycin
A1 (BafA1), or at the stage of hydrolysis by deficiency of the enzyme cathepsin D, led to
enhanced aggregation of polygluatmine, polyalanine, and α-synuclein proteins (Qin et al.,
2003, Ravikumar et al., 2002; Webb et al., 2003; Paxinou et al., 2001; Stefanis et al.,
2001). In contrast, the induction of autophagy leads to increased clearance and reduced
toxicity of pathogenic proteins, decreased aggregate formation and neurodegeneration,
and improved behavioral phenotype in fly and mouse models (Ravikumar et al., 2002;
Webb et al., 2003; Sarkar et al., 2005; Sarkar et al., 2007a, 2007b; Berger et al., 2006;
Ravikumar et al., 2004; Spencer et al., 2009). Stimulation of autophagy has been
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accomplished either by rapamycin, which inhibits the negative regulator of autophapgy
mammalian target of rapamycin (mTOR), by several mTOR independent compounds
including lithium and trehalose, or by lentiviral gene transfer for Beclin-1, a modulator of
autophagy (Ravikumar et al., 2002; Webb et al., 2003; Sarkar et al., 2005; Sarkar et al.,
2007a, 2007b; Berger et al., 2006; Ravikumar et al., 2004; Spencer et al., 2009). (The
previous paragraph is taken from Malkus et al., 2009).
While autophagy appears to play a role in neurodegeneration and clearance of
aggregated proteins, the precise contribution of this proteolytic pathway to various
diseases remains unclear. Various dysfunctions among the autophagic pathway have
been associated with different neurodegenerative diseases. In Huntington’s disease it
appears that autophagosomes are able to be properly formed and cleared. However, a
failure of cargo recognition leads these autophagic vacuoles to have an “empty”
appearance, and consequently results in failed clearance of substrates (Martinez-Vicente
et al., 2010). In Alzheimer’s disease, mutations in Presenilin-1 cause a familial earlyonset form of the disease. Presenilin-1 was recently identified as being crucial for
acidification of the lysosome (Lee et al., 2010).

Mutations in Presenilin-1 were

associated with impaired lysosome acidification and cathepsin activation in cultured cells
and fibroblasts from Alzheimer’s patients(Lee et al., 2010).

The Parkinson’s disease

related protein LRRK2 has been shown to localize with autophagic vacuoles and
mutations in the protein caused the accumulation of large autophagic vacuoles containing
incompletely digested material (Alegre-Abarrategui et al., 2009).

In mice lacking

LRRK2, there are alterations in the lysosomal pathway including impaired
autophagosome formation (Tong et al., 2010). Therefore, it is likely that the unique
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nature of different neurodegenerative may reflect malfunctions of selective aspects of
autophagy.
While macroautophagy remains the only pathway that is able to clear aggregated
proteins (Ravikumar et al., 2002; Iwata et al., 2005; Wong et al., 2008), other degradation
pathways are likely involved in the endogenous degradation of amyloidogenic proteins
while they are in their soluble native state. Dysfunction of one of these processes may
induce the accumulation of the aggregate-prone substrate, thus promoting inclusion
formation and cellular dysfunction. Similar to macroautophagy, microautophagy is a
non-selective process, though it is maintained at a constitutively active state.
Microautophagy involves uptake of substrates into the lysosome via invagination of the
lysosomal membrane into the lysosomal lumen.

The final type of autophagy is

chaperone-mediated autophagy (CMA). Like macroautophagy, CMA is present at low
basal levels in the cell and is upregulated in response to stress. However, CMA is unique
from the other two forms of autophagy in that it involves the selective targeting of
substrates, as well as the direct uptake of substrates into the lysosome through a regulated
receptor

1.5 Chaperone Mediated Autophagy
1.5.1 Overview of a selective pathway of lysosomal degradation
A five amino acid motif biochemically related to the sequence KFERQ forms the
basis for the selectivity of substrate degradation in CMA (Dice et al., 1986; Chiang and
Dice, 1988). Substrate proteins that contain this pentapeptide motif are recognized by the
cytosolic chaperone heat shock cognate protein of 70kDa (Hsc70) (Dice et al., 1986;
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Chiang et

al.,

1989;

Terlecky et al., 1992).
Hsc70, along with cochaperones, targets the
substrate
lysosomal

to

the
receptor

lysosome-associated

Figure 1-3. Chaperone mediated autophagy. In CMA, a substrate
protein containing a KFERQ targeting motif is recognized by Hsc-70
and transported to the lysosomal receptor, Lamp-2A. The substrate is
unfolded and transported through Lamp-2A by lys-Hsc-70. Inside the
lysosome, lysosomal proteases degrade the substrate.

membrane protein type 2A (Lamp-2a) (Cuervo and Dice, 1996) (Figure 1-3).

The

substrate is then unfolded, and, with the help of additional Hsc70 molecules located
within the lysosomal lumen, passes through the Lamp-2a receptor into the lysosome for
degradation. In order for substrates to be efficiently taken up through Lamp-2a and
degraded, Hsc70 and ATP are required (Cuervo et al., 1994; Cuervo et al., 1995).
Approximately thirty percent of cytosolic proteins contain this pentapeptide targeting
motif and consequently are potential substrates for CMA (Chiang and Dice, 1988).
CMA is activated during conditions of cell stress, such as nutrient deprivation,
oxidative stress, and exposure to toxic compounds (Cuervo et al., 1999; Finn and Dice,
2005; Cuervo et al., 1995; 1999; Kiffin et al., 2004). Interestingly, the mechanisms
underlying this activation vary in response to different insults, since nutrient deprivation
initiates a recruitment of already synthesized Lamp-2a to the lysosomal membrane, while
oxidative stress is able to induce new protein synthesis (Cuervo and Dice, Traffic, 2000;
Kiffin et al., 2004; Mak et al., 2010). Blockage of CMA activity by RNAi against the
lysosomal receptor Lamp-2a leads to an initial deregulation of macroautophagy and the
UPS followed by a constitutive upregulation of macroautophagy (Massey et al., 2006,
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2008). Decreased CMA function did not alter the basal viability of cultured cells (Massey
et al., 2006).

However, decreased levels of CMA did leave cultured cells more

vulnerable to UV light or oxidative stress generated by hydrogen peroxide, paraquat, or
cadmium (Massey et al., 2006). Viability in CMA deficient cells exposed to heat or
serum removal was not affected, further supporting the possibility of differential response
to various stressors. Additionally, decreased CMA function increased levels of high
molecular-weight soluble and detergent-insoluble α-syn in cultured cells overexpressing
α-syn (Vogiatzi et al., 2008). CMA activity has been shown to decline with age, due to
decreased levels of the Lamp-2a receptor in the lysosome and altered dynamics of the
receptor at the lysosomal membrane (Dice, 1982; Cuervo and Dice, JBC 2000; Kiffin et
al., 2007). This vulnerability suggests a possible explanation for the age-related onset of
neurodegenerative disease.
1.5.2 CMA and neurodegenerative disease
The KFERQ-related domain that targets select proteins for CMA degradation has
been identified in a number of aggregate prone proteins, including amyloid precursor
protein (APP), huntingtin (htt), tau, and α-synuclein (Massey et al., 2004). Therefore,
regulation of this degradation system may have important effects on the homeostasis of
pathogenic proteins. Research has suggested that CMA may play a role in several
neurodegenerative diseases.
In the brains of patients with Alzheimer’s disease, levels of the CMA chaperone
Hsc70 are increased compared to control brains and have been shown to associate with
neuritic plaques and neurofibrillary tangles (Hamos et al., 1991). Additionally, Hsc70
has been shown to associate with tau and promote its degradation (Shimura et al., 2004;
20

Petrucelli et al., 2004). Tau is a microtubule associated protein that has been found in the
neurofibrillary tangles of Alzheimer’s disease and other tauopathies. Recently, Wang et
al (2009) explored the lysosomal degradation of tau containing the frontotemporal
dementia Δ280 mutation. Abnormal cleavage of this protein results in the generation of
fragments that readily aggregate. This group found that full length wild-type tau and full
length TauΔ280 were able to associate with lysosomes, though not in a CMA-dependent
fashion (Wang et al., 2007). However, a truncated form of the TauΔ280 is able to act as
CMA substrate and was targeted to Lamp-2a via Hsc70. Interestingly, the truncated
mutant tau that was able to associate with Lamp-2a was not able to be taken up into the
lysosome for degradation. Rather, the associated tau was subject to cleavage by the
lysosomal protease cathepsin L, generating amyloidogenic fragments at the lysosomal
membrane that promoted the formation of oligomers (Wang et al., 2007).
In Huntington’s disease, an increased number of repeats of the amino acid
glutamine in the huntingtin protein leads to protein aggregation and neurodegeneration.
While the endogenous role of CMA in the degradation of soluble huntingtin has not been
established, huntingtin does contain five regions with a putative CMA targeting motif. In
cells overexpressing the N-terminus of huntingtin, huntingtin was shown to associate
with Hsc70, and knocking down expression of Lamp-2a increased the levels of huntingtin
(Thompson et al., 2009). Correspondingly, increased levels of Lamp-2a and Hsc70
decreased huntingtin levels and reduced cell toxicity (Thompson et al., 2009). Recently,
Bauer et al. (2010) demonstrated the therapeutic potential of CMA in cell and mouse
models of Huntington’s disease. Polyglutamine binding peptide 1 (QBP1) is a molecule
that is able to selectively bind to the expanded polyglutamine tracts within the pathogenic
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huntingtin protein. The authors fused QBP1 to a CMA pentapeptide binding motif, so
that QBP1 could facilitate recognition of huntingtin by Hsc70.

Cells transfected with

this construct had increased CMA-specific degradation of huntingtin, and injection of this
construct into the brain of a mouse model of Huntington’s disease showed decreased
aggregation of huntingtin, improved motor performance and weight, and increased
lifespan (Bauer et al., 2010).
The protein ubiquitin C-terminal hydrolase L-1 (UCH-L1) has been suggested to
play a role in Parkinson’s disease. An I93M missense mutation in the protein was found
in two German siblings with a dominantly inherited pattern of PD (Leroy et al., 1998),
and UCH-L1 immunoreactivity has been documented in patients with sporadic PD (Lowe
J et al., 1990). UCH-L1 contains a CMA binding motif and has been shown to interact
with Lamp-2a, Hsc70, and Hsp90 (Kabuta T, 2008). The I93M mutation increased the
association of UCH-L1 to Lamp-2a, although the direct uptake of this protein by CMA or
the effect of this mutation on CMA activity has not been documented (Kabuta T, 2008).
This evidence suggests that CMA may play a role in a diversity of
neurodegenerative disorders through orchestrating the levels or lysosomal cleavage of a
variety of potentially pathogenic proteins.

However, the strongest evidence for a

relationship between CMA and a protein associated with neurodegeneration lies with αsynuclein.
1.5.3 CMA and alpha synuclein
While the data from studies examining degradation of α-synuclein by the
proteasome or by macroautophagy has suggested a role for both degradation systems in
α-synuclein homoeostasis, the contribution of each pathway remains controversial.
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Additionally, Lee et al. (2004) reported that in cultured SH-SY5Y cells and primary
embryonic cortical neurons, application of a general autophagy inhibitor induced
accumulation of α-synuclein, but the macroautophagy-specific inhibitor 3-MA failed to
increase α-synuclein levels. Oligomeric aggregates that form in these cultured cells upon
the addition of lysosomal protease inhibitors were additionally shown to co-localize with
Lamp-2 (Lee et al., J Neurosci, 2004).

Therefore, the possible contribution of an

additional, non-macroautophagy lysosomal degradation pathway was explored.
α-Synuclein contains a pentapeptide motif for CMA targeting in residues
95VKKDQ99.

Mutation of the residues DQ to AA prevents the CMA uptake and

degradation of α-synuclein (Cuervo et al., 2004). α-Synuclein is a CMA substrate in
cultured cells and isolated lysosomes (Cuervo et al., 2004; Xilouri et al., 2009; Vogiatzi
et al., 2008; Martinez-Vicente et al., 2008). Additionally, in mice, α-synuclein has been
detected in the lysosomal lumen of midbrain neurons and associates with Hsc-70 and
Lamp-2a (Mak et al., 2010; Vogiatzi et al., 2008). Inhibition of CMA by siRNA against
Lamp-2 induces the accumulation of soluble high molecular-weight and Triton X-100
insoluble α-synuclein in cells (Vogiatzi et al., 2008).
Mutations in α-synuclein or changes in expression level lead to selective effects
on the CMA pathway.

In vitro, α-syn containing the A53T or A30P familial PD

mutations or wild-type α-syn modified by oxidized dopamine binds strongly to the Lamp2a receptor, blocking the uptake and degradation of substrates by CMA (Cuervo et al.,
2004; Martinez-Vicente et al., 2008). Overexpression of A53T α-syn in cultured cells
resulted in decreased lysosomal degradation due to CMA impairment. Additionally,
A53T α-synuclein induced increased cell toxicity while A53T α-synuclein that is not a
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CMA substrate due to mutation in the pentapeptide targeting motif did not, suggesting a
direct consequence of CMA impairment (Xilouri et al., 2009). In mice, increased levels
of α-synuclein due to treatment with paraquat or transgenic overexpression of the wildtype mouse α-syn led to increased levels of Lamp-2a and Hsc70 (Mak et al., 2010). This
increased expression of α-synuclein and CMA components was accompanied by
increased association of α-synuclein with Hsc70 and with lysosomes, indicating targeted
response of the CMA pathway to α-synuclein as a substrate (Mak et al., 2010).
Increased levels of α-synuclein caused by decreased degradation promotes the
propensity of the protein to undergo oxidative or nitrative modifications, oligomerization,
and aggregation. In CMA, substrates must first be unfolded in order to pass through the
Lamp-2a receptor into the lysosome for degradation (Salvador et al., 2000). Therefore,
once the process of aggregation has begun, it is likely that CMA cannot effectively
participate in the clearance of multimeric α-synuclein, magnifying the cascade of
aggregation. Oligomeric α-synuclein was shown to bind to the lysosomal membrane but
was unable to be unfolded or taken up into the lysosomes (Martinez-Vicente et al., 2008).
Additionally, CMA impairment may be affecting neuronal viability through resultant
effects on other proteins. α-Synuclein induced impaired CMA degradation of myocyte
enhancer factor 2D (MEF2D), a transcription factor required for neuronal survival,
resulting in the cytosolic accumulation of MEF2D that bound poorly to DNA, causing an
overall decrease in MEF2D function (Yang et al., 2009).
A role for CMA in α-synucleinopathies is supported by recent findings from
human patients with sporadic PD. Decreased levels of Lamp-2a and Hsc70 were found
in the substantia nigra pars compacta and amygdala of PD patients compared to patients
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with Alzheimer’s disease or controls (Alvarez-Erviti et al., 2010).

Interestingly,

immunohistochemistry revealed that Lamp-2a and Hsc70 immunoreactivity was largely
absent from Lewy bodies and Lewy neurites (Alvarez-Erviti et al., 2010). A second
group supported these findings, examining peripheral leukocytes of PD patients. Wu et
al (2011) found that both the gene expression levels and protein levels for Lamp-2 were
decreased in peripheral leukocytes of PD patients. Both groups also found increases in
LC3 levels patients with PD, which reflects the autophagic vacuole accumulation
documented previously (Anglade et al., 1997; Alvarez-Erviti et al., 2010; Wu et al.,
2011). Levels of other lysosomal proteins, Lamp-1, Cathepsin-D, and Hsp73, along with
the 20S proteasome, have also been documented as being decreased in PD nigral neurons
using immunohistochemistry, with the strongest changes in the neurons with α-synuclein
positive inclusions (Chu et al., 2009).

These data suggest that there is a general

dysfunction of protein degradation in PD, which includes CMA components but may not
be restricted to CMA. However, post-mortem studies are only able to monitor what
changes remain following disease and cannot detect the initial insults which lead to
neurodegeneration. Therefore, it is important to determine what the potential causative
role of CMA in α-synuclein neurodegeneration may be.

1.6 A lysosomal membrane protein directly regulates CMA activity
1.6.1 Lysosomal membrane proteins
Lamp-2a was first identified as the CMA receptor after determining that the
known CMA substrate GAPDH bound to a protein of an apparent molecular weight of
96kDa by far-western blot (Cuervo and Dice,1996). This 96kDa protein was eluted from
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an SDS-PAGE gel and sequenced, and a peptide corresponding to the C-terminal region
of Lamp-2a was identified (Cuervo and Dice, 1996). Lamp-2a belongs to a family of
lysosomal membrane proteins that includes lysosomal integral membrane proteins 1 and
2 (Limp-1 and Limp-2) as well as lysosomal associated membrane proteins 1 and 2
(Lamp-1 and Lamp-2) (Figure 1-4).

These proteins are major constituents of the

lysosomal membrane, together representing over 50% of the total membrane proteins of
late endosomes and lysosomes (Marsh et al., 1987).
All four of these proteins are transmembrane proteins that are heavily
glycosylated, thus helping to protect the lysosomal membrane from the lysosomal
hydrolases. Limp-1 crosses the lysosomal membrane four times while Limp-2 spans the
lysosomal membrane twice,
resulting in both the N and C
termini of the proteins being
located

in

the

cytoplasm

(Vega et al., 1991; Metzelaar
et al., 1991).

Mice lacking

Limp-1, also called CD63,
displayed normal lysosomal
function. Rather, this protein
Figure 1-4. Lysosomal Membrane Proteins. The four major
lysosomal membrane proteins are Limp-1, Limp-2, Lamp-1, and
Lamp-2. These proteins are all heavily glycosylated, with the fork
icon indicating putative N-linked glyocsylation sites, and the
circle icons representing putative O-linked glycosylation sites.
Figure is from Eskelinen et al., TRENDS Cell Biol (13), 2003
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is believed to contribute to
kidney physiology and water
regulation,
development

as
of

well

as

immune

system cells and regulation of platelet adhesion (Schroder et al., 2009; Pols and
Klumperman, 2009). Limp-2, also known as LGP85, plays a role in controlling the
balance of vesicle budding versus vesicle invagination in the biogenesis of lysosomes
from late endosomes (Kuronita et al., 2002). Limp-2 also appears to be important for
myelin maintenance, as Limp-2 deficient mice exhibited a peripheral demyelinating
neuropahy in addition to increased postnatal mortality, lysosome accumulation, and
hearing deficits (Gamp et al., 2003; Knipper er al., 2006).

Additionally, Limp-2

participates in the binding and transport of the enzyme β-glucocerebrosidase to the
lysosome (Reczek et al., 2007).
Lamp-1 and Lamp-2 possess a 37% amino acid sequence homology, and are
structurally very similar. These proteins span the lysosomal membrane once with a short
twelve amino acid C-terminal region extending into the cytoplasm while the majority of
each protein resides in the lysosomal lumen. Lamp-1 and Lamp-2 may have overlapping
functions, as knockout mice for either Lamp-1 or Lamp-2 were viable, yet Lamp1/Lamp-2 double-deficient mice were embryonic lethal (Andrejewski et al., 1999; Tanaka
et al., 2000; Eskelinen et al., 2004). Additionally, Lamp-1 knockout mice displayed an
upregulation of Lamp-2, but not Limp-2 (Andrejewsi et al., 1999). Knockout studies also
suggest that Lamp-2 may have a more selective role than Lamp-1, as indicated by a more
severe phenotype.

Lamp-1 knockout mice are phenotypically normal, with mild

astrogliosis and altered Cathepsin D immunoreactivity being the only differences noted
when compared to wild-type mice (Andrejewski et al., 1999). Alternately, Lamp-2
knockout mice are smaller than their wild type littermates and approximately 50% of the
knockout mice die between postnatal day 20 and 40 (Tanaka et al., 2000). Interestingly,
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the Lamp-2 knockout mice that survive past day 40 live an approximately normal
lifespan. These mice have abnormal cardiac myocytes and reduced heart contractility, a
phenotype that replicates the human cardiomyopathy Danon disease which is caused by
mutations in the Lamp-2 isoform Lamp-2B (Tanaka et al., 2000). However, these mice
also display an accumulation of autophagic vacuoles, particularly early autophagic
vacuoles, and hepatocytes cultured from these mice displayed a decrease in the
degradation of long-lived proteins and an inability to stimulate protein degradation by
serum withdrawal (Tanaka et al., 2000). These data highlight the importance of Lamp-2
for normal lysosomal function and suggest a role for Lamp-2 in maturation and fusion of
autophagic vacuoles to lysosomes. Lamp-2 deficient hepatocytes were found to have
autophagic vacuoles with a prolonged half-life and decreased steady state levels of the
mannose-6-phosphate receptor due to impaired recycling of the receptor from the
endosomes to the golgi (Eskelinen et al., 2002). Additionally, Lamp-2 knockout mice
have severe periodontitis that develops due to an inability to clear bacterial pathogens
because of impaired fusion of the late endosomes and lysosomes with phagosomes
(Beersten et al., 2008). The importance of Lamp proteins for the fusion of lysosomes
with phagosomes has been further documented. However, in these studies deficiency in
just one of the Lamp proteins was not sufficient to induce any alterations (Binker et al.,
2007; Huynh et al., 2007). But when cells lack both Lamp-1 and Lamp-2, they displayed
a decreased mobility of late endosomes and lysosomes as well as phagosomes along
microtubules and consequently impaired fusion between lysosomes and phagosomes
(Huynh et al., 2007; Binker et al., 2007). The location of lysosomes within the cell is
also more dispersed and peripheral, reinforcing the deficits in microtubule trafficking
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(Huynh et al., 2007). Consequently, the Lamp proteins appear to be important not only
for protection of the lysosomal membrane, but also for lysosomal biogenesis and
trafficking.
Lamp-2 molecules are targeted to the lysosome by a tyrosine-based motif in their
C-terminal tail, YEQF, that follows the established targeting motif of a tyrosine, followed
by any two amino acids, followed by an amino acid with a bulky hydrophobic side chain
(Bonifacio and Traub, 2003). It is established that Lamp-2 is transported to the lysosome
by a pathway that is distinct from the mannose-6-phosphate receptor mediated pathway
used for the transport of lysosomal proteases (Karlsson et al., 1998). However, the
precise pathway by which Lamp-2 arrives at the lysosomal membrane is not entirely
understood. Due to the existence of Lamp-2 in both the lysosomes as well as the plasma
membrane, two different routes have been proposed for lysosomal targeting. The first is
a direct route, by which Lamp-2 is transported directly from the golgi to the lysosomes.
This observation is supported by evidence in which the cellular localization of Lamp
proteins were followed by incorporation of radiolabeled sialic acid (Karlsson et al.,
1998). Lamp proteins were found to be distinct from vesicles containing γ-adaptin and
the mannonse-6-phosphate receptor and to migrate differently from vesicles containing
proteins destined for the plasma membrane (Karlsson et al., 1998). However, an alternate
route by which Lamp-2 is first transported to the plasma membrane and is then targeted
to the lysosomes after endocytosis from the plasma membrane has also been proposed
(Storrie et al., 1996). Recent work using fluorescent chromaphores with blue to red
conversion timing that allow the path of a protein to be detected at various timepoints
support this later theory (Subach et al., 2009). Lamp-2a appears to travel from the golgi
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to the plasma membrane, where it is retained for a short period of time before becoming
associated with early and recycling endosomes that transport Lamp-2 to its final
destination in the late endosomes and lysosomes (Subach et al., 2009)
Lamp-2 mRNA undergoes alternative splicing to form three different protein
isoforms with similar sequences in their lysosomal lumen region but unique C-terminal
transmembrane and cytosolic domains. These three different isoforms, Lamp-2a, Lamp2b, and Lamp-2c have different distribution among tissues as well as within the cell
(Konecki et al., 1995; Furuta et al., 1999; Licheter-Konecki et al., 1999; Gough et al.,
1997). While all isoforms demonstrate expression across a variety of tissues , Lamp-2a is
expressed most strongly in the lung, liver, pancreas, kidney, while Lamp-2b is expressed
most strongly in the muscle and brain (Konecki et al., 1995; Licheter-Konecki et al.,
1999). Lamp-2a and Lamp-2b are present at both the cell surface and the lysosomal
membrane, while Lamp-2c is located almost exclusively in the lysosomal membrane
(Gough et al.,1997).
1.6.2 Lamp-2a – A unique lysosomal protein
The splicing of Lamp-2 mRNA to create a unique C-terminus for Lamp-2a is
responsible for the selective role of this isoform in CMA. This region binds CMA
substrates allowing this protein to serve as the CMA receptor through which substrates
enter the lysosome. Of the twelve amino acids located in this cytosolic C-terminal
region, Lamp-2b and Lamp-2c differ in eight and nine of the amino acids, respectively.
Site directed mutagenesis of the cytosolic tail of Lamp-2a revealed that a series of four
positive residues (KHHH) is responsible for substrate binding (Cuervo and Dice, 2000b).
In the mouse, this series of four amino acids is slightly modified to KRHH but retains its
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positive charge. Accordingly, immunoprecipitation studies demonstrated that the CMA
substrate GAPDH is able to associate with Lamp-2a but not the other isoforms of Lamp-2
(Cuervo and Dice, 2000b).
The importance of the Lamp-2a receptor to the process of chaperone mediated
autophagy has been highlighted by the finding that the levels of Lamp-2a protein, but not
the levels of Lamp-1 or the levels of the combined isoforms of Lamp-2, change
proportionally to CMA activity (Cuervo and Dice, 2000b).

Additionally, a sub-

population of lysosomes has been found to have a larger amount of Hsc70 within the
lysosomal matrix and have a higher level of CMA activity (Cuervo et al., 1997). These
“CMA active” lysosomes have a larger proportion of Lamp-2a in the lysosomal
membrane compared to the lysosomal matrix, at levels that correlated with the
lysosomes’ degradation of GAPDH (Cuervo and Dice, 2000b).

Analysis of CMA

activity in lysosomes isolated from rats following different periods of starvation showed
that the increase in CMA activity that occurs with starvation is proportional to an increase
in Lamp-2a expression (Cuervo and Dice, 2000b). Expression of Lamp-1 or all isoforms
of Lamp-2 does not show this correlation (Cuervo and Dice, 2000b). This proportional
relationship between Lamp-2a expression and CMA activity has suggested that Lamp-2a
is the rate limiting step in this pathway.
Both overexpression and knockdown studies have reinforced the relationship
between Lamp-2a levels and CMA activity. Overexpression of human Lamp-2a in CHO
cells led to increased rates of protein degradation proportional to Lamp-2a expression and
increased degradation of GAPDH in an in vitro activity assay (Cuervo and Dice, 1996).
Aged mice typically display decreased levels of Lamp-2a and decreased clearance of
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proteins. Introduction of an inducible Lamp-2a transgene with a liver-specific promoter
into mice led to increased protein degradation in aged mice and improved liver function
(Zhang and Cuervo, 2008). Alternately, application of RNAi directed against Lamp-2a to
cultured cells led to significantly decreased levels of degradation of two established CMA
substrates (Massey et al., 2006).
While the cytosolic region of Lamp-2a is critical for substrate recognition and
CMA activity, the majority of the protein is located with the lysosomal lumen, and
modification of this lysosomal portion with glycans is critical for the stability of the
protein.

Lamp-2a is one of the most highly glycosylated proteins in the cell. It is

decorated with 4 O-linked and 16 N-linked glycans, the majority of which are complex
oligosaccharides, particularly poly-N-acetyllactoasmines (Carlsson et al., 1988; Carlsson
et al., 1990; Carlsson et al., 1993). These glycans are critical for protecting the protein
from degradation by the proteases in the lysosomal lumen. Removal of the N-linked
glycans has been shown to result in rapid degradation of Lamp-2 (Barriocanal et al.,
1986; Kundra et al., 1999).
The levels of Lamp-2a at the lysosomal membrane are regulated by two different
processes, first by the half-life of the protein, but also by a dynamic redistribution of the
protein between the lysosomal matrix and the lysosomal membrane. Lamp-2a within the
lysosomal membrane is released for degradation by sequential cleavage by a
metalloprotease followed by Cathepsin A (Cuervo and Dice, 2000a; Cuervo et al., 2003).
This discharges Lamp-2a into the lysosomal matrix where it is degraded by lysosomal
proteases (Cuervo and Dice, 2000a). This degradation of Lamp-2a is a regulated process
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that is inihibited by both the presence of CMA substrates and conditions that activate
CMA activity (Cuervo and Dice, 2000a).
Alternately, during conditions that activate CMA, such as nutrient deprivation or
oxidative stress, intact Lamp-2a undergoes dynamic redistribution between the lysosomal
membrane and matrix to regulate Lamp-2a membrane levels. In the presence of CMA
substrates, Lamp-2a is internalized from the lysosomal membrane to the matrix,
presumably by the same uptake process as the substrate itself undergoes, occurring at a
rate of approximately one Lamp-2a molecule for every 8-10 substrate molecules (Cuervo
and Dice, 2000a). This results in a decrease of Lamp-2a at the lysosomal membrane in
the presence of substrates that saturates and is proportional to the amount of substrate
taken up. In the absence of substrate proteins, but during starvation conditions, Lamp-2a
is able to reinsert in the lysosomal membrane in a process that requires the chaperone
protein Hsc70 (Cuervo and Dice, 2000a). This dual approach allows for both more
permanent control of CMA activity, through Lamp-2a degradation, as well as a more
transient modulation that can permit a dynamic response to changing conditions.
Substrate proteins bind to Lamp-2a while the receptor is a monomer.

The

monomeric form of Lamp-2a is located within cholesterol/glycosphingolipid-rich
microdomains of the lysosomal membrane and is more susceptible to proteolytic
cleavage and degradation (Kaushik et al., 2006). However, for translocation of the
substrate into the lysosome, Lamp-2a must form a multimeric complex, a process which
takes place outside of the lipid-enriched membrane regions (Kaushik et al., 2006;
Bandyopadhyay et al., 2008).

This complex has been estimated to be approximately

700kDa, though multiple components other than Lamp-2a are likely associated
33

(Bandyopadhyay et al., 2008). The chaperone Hsc70 promotes the disassembly of the
multimeric complex into the monomer, while Hsp90 is responsible for mulimerization
and stability of the protein (Bandyopadhyay et al., 2008). Mutation of two glycine
residues in the transmembrane domain that resemble a dimerization motif described for
other proteins was shown to decrease the multimerization of Lamp-2a. This mutation
resulted in increased substrate binding but decreased rates of protein degradation
(Bandyopadhyay et al., 2008). Similarly, alteration of the cholesterol profile of the
lysosomes affects the distribution of Lamp-2a between the monomeric and multimeric
forms and consequently impacts CMA activity. Cholesterol depleting agents increase
CMA activity, while loading the lysosomes with cholesterol reduces CMA activity
(Kaushik et al., 2006). These studies provide strong evidence that Lamp-2a is the ratelimiting step for CMA. Consequently, investigating the relationship between Lamp-2a
and α-synuclein neurodegeneration may provide valuable insights into the mechanisms
underlying disease.

1.7 Rationale and Overview
Despite extensive study of the interaction between α-synuclein and various
protein degradation systems, several unresolved issues remain. While catastrophic failure
of these pathways permits the aggregation of amyloidogenic proteins, it is not known
how these degaradation systems may contribute to regionally selective formation of αsynuclein inclusions. Since α-synuclein has been identified as a substrate of the CMA
degradation pathway, this thesis is focused on examining how regionally selective
alterations in the interplay between CMA and α-synuclein contribute to disease. To
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investigate this, a previously characterized mouse model of synucleinopathy was
employed. These mice are transgenic for human α-synuclein with the A53T mutation.
At approximately twelve months of age, these mice develop age-dependent motor
dysfunction and α-synuclein positive cytoplasmic inclusions that are most abundant in the
brainstem and spinal cord (Giasson et al., 2002).
In Chapter 2, regional differences in lysosomal function will be explored to
determine if lysosomal impairment plays a role in the selectivity of α-synuclein
neurodegeneration. Specifically, CMA will be the focus of these investigations, with
examination of Lamp-2a expression, lysosomal binding, and lysosomal uptake and
degradation.
Following the determination that differences in lysosomal function exist in
regions that are more prone to developing α-synuclein inclusions, Chapter 3 will explore
potential factors that leave α-synuclein selectively vulnerable to aggregation. First, the
ability of the CMA chaperone Hsc70 to bind α-synuclein will be examined. Because
lysosomal uptake of substrates by CMA requires proteins to be unfolded, the native state
and solubility of α-synuclein will be investigated next. Additionally, lipids have been
proposed to play a role in both α-synuclein aggregation and lysosomal dysfunction.
Therefore, levels of the Apolipoprotein E (ApoE) and low-density lipoprotein receptor
(LDLR) were examined to determine if differences in lipid metabolism may contribute to
α-synuclein aggregation.
Chapter 4 will expand upon the observation that levels of Lamp-2a do not
correlate with CMA activity in the brain. This chapter will explore the possibility that
additional lysosomal proteins may participate in the direct uptake and degradation of
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substrates.

The glycoslyation and stability of Lamp-2a is discussed, and a 96kDa

lysosomal protein is investigated. Specifically, the possibility of Lamp-1 serving as an
additional lysosomal receptor is explored.
Finally, chapter 5 will conclude with a summary and discussion of the
implications for this work. Future directions for further investigation of unresolved
questions will also be explored. This work will provide novel insights into the role of
regionally selective lysosomal deficiencies and their contribution to α-synuclein
neurodegeneration.
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CHAPTER 2
Lysosomal insufficiency underlies the regional
selectivity of α-synuclein neurodegeneration.

By:
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2.1 Abstract
The characteristic accumulation of aggregated proteins such as α-synuclein (α-syn) in
neurodegenerative disorders suggest that altered protein homeostasis is an underlying
cause of disease. However, it remains unclear how α-syn aggregation occurs in distinct
areas of the brain. Herein, we explored if alterations in the lysosomal degradation
pathway of chaperone mediated autophagy (CMA) contribute to the selective regional
formation of α-syn inclusions in mice expressing human A53T α-syn. Comparing the
expression of the CMA receptor Lamp-2a across brain regions revealed higher levels of
Lamp-2a in the brainstem and spinal cord, two areas that develop prominent α-syn
inclusions. However, the inclusion forming regions demonstrated decreased levels of
Cathepsin D and LC3-II/LC3-I, indicating lower numbers of lysosomes and
autophagosomes. Furthermore, upon the development of symptoms in the A53T α-syn
mice, a significant increase in Lamp-2a mRNA and protein levels occurred in brainstem
and spinal cord. Despite the increased Lamp-2a levels, the brainstem and the spinal cord
exhibit functional impairments in substrate binding and CMA activity. The rate of CMA
substrate degradation, adjusted for the levels of Lamp-2a, was significantly lower in these
inclusion-prone regions as compared to regions that do not develop α-syn inclusions.
Collectively the data suggests that regional deficiencies in lysosomal content and
function provide a potential mechanism for the selective initiation of α-syn aggregation
and ultimately neurodegeneration in the mouse brain.
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2.2 Introduction
α-Synuclein (α-syn) has been identified as an integral component of the protein
inclusions found in several related neurodegenerative disorders, including Parkinson’s
disease (PD) (Spillantini et al., 1997, 1998a,b). Although α-syn is expressed throughout
the brain and in many other organs, inclusions are found predominantly in select brain
regions (Uéda et al., 1993; Iwai et al., 1995; Duda et al., 2002). The aggregation of α-syn
is in part facilitated by protein levels, evidenced by in vitro studies as well as cases of
familial PD with increased gene dosage (Conway et al., 1998; Giasson et al., 1999;
Chartier-Harlin et al., 2004). While much research has consequently focused on the
protein degradation pathways that dictate α-syn homeostasis, these pathways are
ubiquitously expressed.

Therefore, the molecular mechanisms underlying the

vulnerability of distinct brain regions to neurodegeneration remain unknown.
α-Synuclein has been shown to be preferentially degraded by CMA (Cuervo et al.,
2004).

In CMA, cytosolic proteins containing a pentapeptide targeting motif are

selectively recognized by the chaperone heat shock cognate protein 70kDa (hsc70).
Hsc70 targets the substrate to the lysosomal receptor lysosome-associated membrane
protein type 2A (Lamp-2a), through which the substrate passes into the lysosome where it
is degraded (Cuervo and Dice, 1996). Similar to macroautophagy, CMA is activated
during conditions of cell stress (Cuervo et al., 1995; 1999; Kiffin et al., 2004). Decreased
CMA function has been shown to leave neurons vulnerable to multiple insults (Massey et
al., 2006) and has been shown to increase levels of high molecular-weight soluble and
detergent-insoluble α-syn in cultured cells (Vogiatzi et al., 2008). A recent study found
that Lamp-2a levels were decreased in α-syn inclusion-forming regions of the substantia
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nigra and amygdala of PD patients compared to control subjects and Alzheimer’s patients
(Alvarez-Erviti et al., 2010).
In vitro, α-syn containing the A53T or A30P familial PD mutations or wild-type
α-syn modified by oxidized dopamine binds strongly to the Lamp-2a receptor, blocking
the uptake and degradation of substrates by CMA (Cuervo et al., 2004; Martinez-Vicente
et al., 2008). Overexpression of α-syn has been shown to impair CMA and increase cell
toxicity in cultured cells (Xilouri et al., 2009). In mice, overexpression of wild-type
mouse α-syn led to increased levels of Lamp-2a and Hsc70 (Mak et al., 2010). While
these data illuminate an important interplay between CMA and its substrate α-syn, it is
unclear how this interaction contributes to the regionally and temporally selective
aggregation of α-syn that occurs in vivo. To investigate this, we used a previously
characterized transgenic mouse model expressing human A53T α-syn (Giasson et al.,
2002). At approximately twelve months old, these mice develop age-dependent motor
dysfunction and α-syn positive cytoplasmic inclusions that are most abundant in the
brainstem and spinal cord (Giasson et al., 2002).

In the present study we identify

multiple functional lysosomal alterations in the regions prone to developing α-syn
inclusions. The deficiencies in these pathogenic regions culminate in lysosomes that
have impaired kinetics of substrate binding and decreased ability to take up and degrade
substrates despite upregulated levels of Lamp-2a.

2.3 Materials and Methods
Mouse breeding. The mice used in this study express human A53T α-syn (line M83)
driven by the murine PrP promoter (Jackson Laboratory, Bar Harbor, Maine) and have
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been described previously (Giasson et al., 2002).

To generate the A53T+/+ and

nontransgenic (nonTg) mice used in experiments, heterozygous A53T+/- females were
mated with A53T+/- males. Genotyping was performed by both end-point PCR using
GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, Carlsbad, CA) and
quantitative PCR using Applied Biosystems 7500 real-time PCR System with the ABI
MGB primer-probe set for human SNCA, the gene that encodes α-syn (Applied
Biosystems assay ID Hs00240907_m1). SNCA values were normalized to mouse β-actin
(Applied Biosystems assay ID 4352341E). The Lamp-2 knockout mice used in this study
have been described previously (Tanaka et al., 2000).
Brain dissection for biochemical analysis. For analysis of brain regions, symptomatic
A53T+/+ α-syn transgenic mice (12 to 17 months old) were euthanized 1-2 days after
initial motor symptom onset as identified by spine stiffness, weight loss, and hindlimb
paralysis as described previously (Giasson et al., 2002). Non-symptomatic A53T+/+ αsyn mice and non-transgenic mice were euthanized at an age matched within two weeks
to the symptomatic mouse of that experimental group. Additionally, young A53T+/+ αsyn mice (2.5 months old) were euthanized for the experiments. Mice were anaesthetized
with CO2 followed by cervical dislocation. The brain and spinal cord were dissected and
rinsed thoroughly with ice-cold phosphate buffered saline (PBS). After dissection of the
cerebellum, olfactory bulbs, and brainstem, the remainder of the brain was submerged in
ice-cold PBS and sliced into 1 mm thick coronal sections using a vibratome (World
Precision Instruments, Sarasota, FL). The brain regions of the hippocampus, cortex,
striatum, and substantia nigra were dissected away from these sections. Dissected brain
regions were weighed, rapidly frozen on dry ice, and stored at -80°C until analysis. For
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analysis of the hippocampus and spinal cord from mice of all four groups, tissue from the
two brain regions was divided evenly between the RNA and western blot experiments so
that the results were paired. The cortex and brainstem of these same mice were used for
crude lysosome extractions so as to conserve the number of mice sacrificed.
RNA isolation and RT-PCR. RNA was extracted from the hippocampus and spinal cord
using the TRIzol reagent (Invitrogen, 15596-026), and cDNA was synthesized using the
Superscript II First Strand Synthesis System for RT-PCR (Invitrogen 11904-018).
Quantitative PCR was performed on this cDNA using Applied Biosystems 7500 real-time
PCR System with the ABI MGB primer-probe set for Lamp-2a (Applied Biosystems
assay ID mM00495274_m1).

Lamp-2a values were normalized to neuron specific

enolase (NSE) (Applied Biosystems assay ID mM00469062_m1)
Western Blotting. Tissue was homogenized with 10 volumes of lysis buffer [50mM Tris
(pH7.5), 150mM NaCl, 5mM EDTA, 10% Glycerol, 1% TritonX-100, 0.5% Sodium
Deoxycholate, 2% Sodium Dodecyl Sulfate (SDS), 8M Urea, 1mM PMSF, 1:50 Protease
Inhibitor Cocktail (Sigma P8340)]. Similar results were seen with the use of an alternate
lysis buffer [20mM HEPES (pH7.4), 150mM NaCl, 10% Glycerol, 1% TritonX-100,
1mM EGTA, 1.5mM MgCl2, 1mM PMSF, 1:50 Protease Inhibitor Cocktail (Sigma
P8340)]. The tissues were homogenized with the aid of a mechanical homogenizer
(Fisher Jumbo Stirrer 14-501) and then subjected to four consecutive freeze and thaw
cycles of 2 min each (-80 °C ethanol bath / 37 °C water bath). The sample was then
centrifuged for 30 min at 18,000xg at 4 °C. The supernatant was retained and protein
concentration was determined by the microBCA assay (Thermo Fisher Scientific,
Rockford, IL). Unless otherwise indicated, 30 μg of material was loaded per lane for
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analysis by SDS-PAGE/western blot.

The tissue was analyzed with the following

primary antibodies : 1:300 Lamp-2a (Invitrogen 51-2200); 1:4000 NSE (Polysciences
Inc. 16625), 1:1000 Hsc70 (Abcam ab2788), 1:1000 α-syn specific for human α-syn
(Syn211, Sigma S5566), 1:10,000 GAPDH (Sigma G9545), 1:2000 β-tubulin (Sigma T4026), 1:500 LC-3 (Novus Biologicals NB100-2220), 1:750 Cathepsin D (Abcam
Ab6313). Similar immunoreactivity for Lamp-2a was observed with 1:300 Lamp-2a
(Abcam ab18528).

Primary antibodies were detected with one of the following

conjugated secondary antibodies: goat anti-rabbit IgG IRDye680 (1:5000, Rockland),
donkey anti-mouse IgG IRDye800 (1:5000, Rockland), donkey anti-mouse IgG
IRDye680 (1:5000, Rockland) and scanned with the Odyssey Infrared Imaging System
(Li-Cor Biosciences, Lincoln, NE). The protein bands from the western blots were
quantified by densitometry using Odyssey infrared imaging system software (Odyssey
version 2.1, Li-Cor Biosciences, Lincoln, NE).
Deglycosylation assay. Fifty micrograms of homogenate from the hippocampus and
spinal cord of non-transgenic mice was denatured for 5 min at 100 °C, briefly cooled, and
then incubated at 37 °C with a cocktail of enzymes that perform N- and O- linked
deglycosylation; PNGaseF; α-2(3,6,8,9) Neuraminidase; O-Glycosidase; β (1-4)
Galactosidase; β-N-Acetylglucosaminidase; Endoglycosidase H (3.33 µl each; Sigma EDEGLY Kit, and Sigma A0810) for varying times. After incubation, the enzymes were
heat inactivated, and the samples were analyzed by SDS-PAGE/western blot.
Crude Lysosome Extraction for Western blots. Brain tissue was homogenized in Trisbuffered 0.25M Sucrose (pH 7.4) with 1:50 Protease Inhibitor Cocktail (SigmaP8340)
and centrifuged at 6,800xg 15 min at 4°C. After washing the pellet with sucrose, the
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combined supernatants were centrifuged at 21,000xg 30 min at 4 °C. The supernatant
was retained as the “cytoplasmic fraction” and the pellet, which contained the light
mitochondria and lysosomes (light M+L fraction), was washed with sucrose and resuspended in lysis buffer. For isolation of the lysosomal membrane fraction, the light
M+L fraction was burst by hypotonic shock. The light pelleted M+L fraction was
obtained as above and re-suspended in 25 µl cold 0.025M Sucrose. The samples were
then centrifuged at 150,000xg for 30 min at 4 °C. The supernatant represents the
lysosomal lumen, while the pellet, which was re-suspended in lysis buffer, is comprised
of the lysosomal membrane.
Lysosomal Purification. In order to obtain a purified lysosomal fraction for use in the
lysosomal activity assay, mitochondria were separated from lysosomes of the light M+L
fraction as follows. The brain from a non-transgenic mouse was separated into the
brainstem and the spinal cord (“pathogenic regions”) and the remainder of the brain
(“non-pathogenic regions”). The light M+L fraction was obtained as described above,
but without the addition of the protease inhibitor cocktail, and was re-suspended in 0.25
M Sucrose instead of lysis buffer. The mitochondria were then precipitated out of the
M+L fraction by incubation with 115 µM CaCl2 for 30 min. The sample was then
centrifuged 5,000xg for 10 min at 4 °C to pellet the mitochondria. The supernatant,
which contains the lysosomes, was collected and centrifuged again at 5,000xg for 10 min
at 4 °C to ensure purity. The supernatant was retained and centrifuged at 21,000xg for 30
min at 4 °C to pellet the lysosomes. The lysosomes were then re-suspended in 300 µl
reaction buffer (10mM MOPS, pH 7.3, 0.25M Sucrose, 5.4µM cysteine, 1mM DTT).
Protein concentration was measured by a micro-BCA protein assay, and lysosomal
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integrity was verified by an assay measuring the activity of the lysosomal enzyme βHexosaminidase with the flourogenic substrate 4-methylumbelliferyl-N-acetyl-βglucosaminide dehydrate (Sigma M2133) in a fraction of lysosomes compared to the nonsediment medium. The enrichment of lysosomes and absence of mitochondria from this
lysosomal fraction was verified by western blot with antibodies against Lamp-2a (Abcam
ab18528) and cytochrome c oxidase subunit 1 (MTCO1) (Abcam ab14705).
In gel digestion and MS/MS analysis. Duplicate samples of 50μg of lysosomes and
lysosomal membranes purified as described above were mixed with 6X Laemmli sample
buffer and separated on a 10% Bis-tris Novex Nupage gel (Invitrogen NP0301). One set
of the lysosomes and lysosomal membranes was analyzed by western blot for Lamp-2a as
described above. For the other set of lysosomes and lysosomal membranes, the gel was
visualized by colloidal blue stain (Invitrogen LC6025). Stained gels were processed by
in-gel trypsin digestion according to the following protocol. Slices were cut from the gel
at apparent molecular weights corresponding to the Lamp-2a bands in the parallel
western blot. Each slice was placed in single well of an Axygen plate and de-stained
with 110 µl of de-stain buffer (50% methanol, 1% acetic acid, 49% water) overnight at
room temperature on a rotator. Destained gel pieces were dehydrated in 100ul of
acetonitrile (ACN) for 5min at room temperature. Acetonitrile was aspirated off and
5mM Tris(2-carboxyethyl) phosphine hydrochloride (TCEP) in 50mM ammonium
bicarbonate buffer was added for 15 minutes at 37 oC in order to reduce cysteine thiols.
Subsequently, cysteine thiols were alkylated with 50mM iodoacetamide in 25mM
ammonium bicarbonate buffer for 30 minutes at 37 oC in the dark. Iodoacetimide
treatment results in additional mass of 57 amu to the cysteine thiol and the
45

carboxyamidomethylated cysteine is used as a static modification when the experimental
data is searched against theoretical databases. In the next step the gel pieces were
dehydrated with 100 µl acetonitrile and hydrated with 100 µl of 10mM AmBic for 5
minutes at room temperature. Next, 100 µl of acetonitrile were added for 5 minutes
followed by 50 µl of 10mM AmBic containing 10ng/ul of trypsin. Trypsin digestion was
performed for six hours at 37 oC. Tryptic peptides were extracted from the gel with 50ul
of 0.3% formic acid for 2 hours at room temperature on a rotator. Supernatants (about
100 µl) were transferred to Axygen tubes and gel pieces were incubated with 50% ACN
for additional two hours at room temperature. Liquid was recovered and combined with
formic acid extracts. The volume was reduced to 5 µl with speedvacing and adjusted to
the desired volume (about 15 µl) with 0.1% formic acid. Tryptic peptide digests were
analyzed by hybrid LTQ-Orbitrap mass spectrometer (Thermo Electron, San Jose, CA)
coupled to an Eksigent 2D LC system (Eksigent Technologies, Livermore, CA) and
autosampler. Buffers A and B were 0.1 % formic acid/1 % methanol and 80%
acetonitrile/0.1 % formic acid/1 % methanol, respectively. Peptides were loaded
isocratically onto a C18 trap column (75 um i.d. x 25 mm; New Objective Proteopep 2) at
a flow rate of 1 μl per minute in 2% B. Peptides were then eluted onto a C18 analytical
column (75 um i.d. x 150 mm; New Objective Proteopep 2). A linear gradient was then
initiated at a flow rate of 300 nL per minute for 90 min from 3 - 40% B. The mass
spectrometer was set to repetitively scan from 375 to 1600 m/z followed by datadependent MS/MS scans on the five most abundant ions with dynamic exclusion enabled.
Generation and evaluation of SEQUEST peptide assignments. DTA files were generated
from MS/MS spectra extracted from the RAW data file (intensity threshold of 2500;
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minimum ion count of 50) and processed by the ZSA and Correction algorithms of the
SEQUEST Browser program. DTA files were submitted to Sorcerer-SEQUEST (ver.
4.0.3, rev 11; Sagen Research, San Jose, CA) using the following parameters: Database
searching was performed against a Uniprot database (Release v3.57; 3/24/2009)
containing Mus musculus sequences from Swiss-Prot plus common contaminants, which
were then reversed and appended to the forward sequences. The database was indexed
with the following parameters: mass range of 600 – 3500, tryptic cleavages with a
maximum

of

2

missed

cleavage

and

static

modifications

of

cysteine

by

carboxyamidomethylation (+57 amu). The DTA files were searched with a 50 ppm
peptide mass tolerance for LTQ-Orbitrap, 1.0 amu fragment ion mass tolerance, and
variable modification of methionine (+16 amu) for in-gel digestion, and maximum
number of variable modifications of 3.

Potential sequence-to-spectrum peptide

assignments generated by Sorcerer-SEQUEST were loaded into Scaffold (version 2.2;
Proteome Software, Portland, OR) to validate protein identifications.

Protein

identifications were accepted at a threshold of ≥ 99 % protein confidence with ≥ 2 unique
peptides at ≥ 80 % confidence. These criteria resulted in an estimated protein false
discovery rate (FDR) of ≤ 5 %, as calculated by the number of hits to the reverse protein
sequences.
Lysosomal Activity Assays with exogenous α-Synuclein.

Human recombinant α-syn

protein used for the assay was expressed and purified as described previously (Giasson et
al., 1999). Twenty five micrograms of lysosomes purified as described above were
incubated for 30 min at 37 °C with 0.2 µg of purified human α-syn, 10 µl of “6x Energy
Regenerating System” (60mM MgCl2, 60mM ATP (Sigma A2383), 12mM
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phosphocreatine, 30µg creatine phosphokinase, in 0.25M Sucrose, pH 7.4), 0.6µg Hsc70
(Enzo Life Science, Farmingdale, NY), and brought up to 60 µl with reaction buffer
(10mM MOPS, pH 7.3, 0.25M Sucrose, 5.4µM Cysteine, 1mM DTT).

Control

conditions were run in parallel with either no lysosomes or no 6x Energy Regenerating
System, in which proteolysis buffer was substituted for the subtracted component, or with
burst lysosomes. For the burst lysosomes, 25 µg of lysosomes were centrifuged at
21,000xg for 8 min at 4 °C. The supernatant was discarded and the pelleted lysosomes
were subjected to hypotonic shock by re-suspension in 0.025M Sucrose (pH 7.4) for 30
min on ice followed by two cycles of freeze/thaw. These burst lysosomes were then
added to the assay in place of the intact lysosomes. For the burst lysosomes, the neutral
reaction buffer used for the intact lysosomes was replaced with an acidic reaction buffer
(10mM citrate buffer, pH 5.0, 0.25M Sucrose, 5.4µM cysteine, 1mM DTT). At the end
of the assay, the reaction was stopped by 1:30 Protease Inhibitor Cocktail (SigmaP8340)
and 1mM PMSF. Samples were subjected to SDS/PAGE alongside standards of purified
human α-syn followed by western blot with a human specific α-syn antibody (Syn211,
Sigma S5566).
Endogenous Degradation Assays. Seventy five micrograms of lysosomes purified as
described above were incubated at 37°C with 5 µl of “6x Energy Regenerating System”
(60mM MgCl2, 60mM ATP (Sigma A2383), 12mM phosphocreatine, 30µg creatine
phosphokinase, in 0.25M Sucrose, pH 7.4), and brought up to 30 µl with reaction buffer
(10mM MOPS, pH 7.3, 0.25M Sucrose, 5.4µM Cysteine, 1mM DTT). As a control
condition, one set of samples was incubated at 4 °C rather than 37 °C, and one set of
samples received additional reaction buffer in place of the 6x energy regenerating system.
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At the end of the assay, the reaction was stopped by adding 1:30 Protease Inhibitor
Cocktail (SigmaP8340) and 1 mM PMSF.

Samples were subjected to SDS/PAGE

followed by western blot with an antibody against GAPDH (Sigma G9545).

To

determine rates of GAPDH degradation, the intensity of the bands of GAPDH were
compared to the intensity of known standards of purified GAPDH protein (Sigma
G5262). The corresponding number of micrograms of GAPDH in the condition with no
incubation and the 15hr time point were calculated. From those values the number of
micrograms of GAPDH degraded per hour was determined. The resulting values were
then divided by the relative levels of Lamp-2a in each region as determined by western
blot.
Statistical Analysis. Data were analyzed using the Graphpad Prism Software (version
5.02) and were expressed as the mean ±SEM. One-way analysis of variance (ANOVA)
with a Tukey’s post-hoc test was used to determine whether groups with multiple
conditions were significantly different. A Paired t-test was used to determine whether
paired groups were significantly different. p values <0.05 were considered statistically
significant.

2.4 Results
Increased levels of Lamp-2a in the mouse brainstem and the spinal cord.
The expression of the lysosomal CMA receptor Lamp-2a has been shown to
directly correlate with CMA activity (Cuervo and Dice, 2000a; 2000b). Therefore, the
levels of this protein were examined in the mouse brain. Within the brain and spinal
cord, two principle immunoreactive bands were identified using an antibody generated
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against the C-terminal region of Lamp-2a (Invitrogen 51-2200), (Figure 2-1A). This
antibody was generated using amino acid residues 399-411 of rat Lamp-2a as antigen and
has been employed for the characterization of this receptor in the rat liver (Cuervo et al.,
1996). This amino acid sequence G399LKRHHTGYEQF411 is identical between rat and
mouse, is located in the putative cytosolic domain of Lamp2a and has very low homology
with the sequence of Lamp2b and Lamp2c isoforms. Based on calibration of the gels
with standard proteins, the apparent molecular weight of the two bands was calculated to
be 96 and 72 kDa. Mouse Lamp-2a is a 415 amino acid protein with a 45,647 Da
backbone that is heavily glycosylated. The molecular weight of the glycosylated form of
the protein in the mouse liver has previously been described to be 96 kDa (Cuervo et al.,
1996).
In order to validate the identity of these two immunoreactive bands, the antibodies
used in this study were reacted with brain homogenates from Lamp-2 knockout mice that
are deficient in all three isoforms of the Lamp-2 protein (Tanaka et al., 2000). This
revealed that the 96kDa band recognized by the Lamp-2a antibody is present in the
Lamp-2 knockout mice whereas the band with an apparent molecular weight of 72kDa is
absent from Lamp-2 knockout mice (Figure 2-1B). Similar data were obtained with a
second polyclonal anti-Lamp-2a antibody (Abcam 18528) (data not shown). The identity
of the 72 kDa band as Lamp-2a was reinforced by mass spectrometry. A purified
lysosomal fraction and a lysosomal membrane fraction from the brainstem and spinal
cord were separated on SDS-PAGE gels. From both fractions bands corresponding to
96kDa and 72kDa were excised and digested with trypsin. The corresponding tryptic
peptides were analyzed by mass spectrometry. Four unique peptides corresponding to
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sequences in Lamp-2 were identified in the 72kDa band from both the enriched
lysosomal fraction and the lysosomal membrane fraction (Table 2-1). However, no
peptides corresponding to Lamp-2 were identified in the 96kDa band indicating that the
72 kDa band represents Lamp-2a in the mouse brain.

Table 2-1. Lamp-2 peptides detected in the 72kDa fraction of lysosomes and lysosomal
membranes. Gel slices corresponding to the 96kDa and 72kDa immunoreactive bands of Lamp-2a were
excised from SDS-PAGE gel of purified lysosomes or purified lysosomal membranes and after digestion
with trypsin, peptides were analyzed by mass spectrometry. Four different peptides corresponding to
Lamp-2 were identified in the 72kDa band, but no Lamp-2 peptides were identified in the 96kDa band.

Consequently, future analysis focused on the 72kDa band. While Lamp-2a has
previously been characterized as being a 96kDa protein in the mouse liver, the lower
molecular weight observed in the brain is likely due to differential glycosylation of the
protein. Lamp-2a is glycosylated with 16 N-linked and 4 O-linked glycans that serve to
protect the protein from the proteases in the lysosome (Carlsson et al., 1988; Carlsson et
al., 1990; Carlsson et al., 1993). The 72 kDa isoform was readily deglycosylated within
10 minutes, resulting in immunoreactivity of a band of approximately 45 kDa
corresponding to the deglycosylated backbone of Lamp-2a (Figure 2-1C). This provides
further support for the identity of this 72 kDa band as Lamp-2a and indicates that the
discrepancy in size from previous characterization of the protein is due to differences in
glycosylation, not improper cleavage of the protein.
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Figure 2-1. Lamp-2a characterization in the mouse brain. A, The brain and the spinal cord from
non-transgenic littermates of the A53T α-syn mice were analyzed by SDS-PAGE/western blot for Lamp2a (Invitrogen 51-2200). Two distinct bands were identified at 96kDa (asterisk) and 72kDa (arrow). B,
The brainstem, spinal cord, and remainder of the brain excluding these regions “Brain (–) BS” were
dissected from non-transgenic littermates of the A53T α-syn mice or from Lamp-2 knockout mice. This
tissue was analyzed by SDS-PAGE/western blot for Lamp-2a using the Invitrogen #51-2200 Lamp-2a
antibody. The 96kDa band (asterisk) but not the 72kDa band (arrow) was recognized by the antibody in
the Lamp-2 knockout mice. C, The hippocampus (Hipp) and spinal cord (SC) of an non-transgenic
mouse were incubated with a cocktail of N- and O- linked deglycosylating enzymes (PNGaseF; α2(3,6,8,9) Neuraminidase; O-Glycosidase; β(1-4) Galactosidase; β-N-Acetylglucosaminidase;
Endoglycosidase H). After incubation, the enzymes were heat inactivated, and the samples were
analyzed by SDS-PAGE/western blot for Lamp-2a. α-Tubulin was used as a loading control. D, The
brains of non-transgenic mice were dissected into eight specific regions and analyzed by SDSPAGE/western blot for Lamp-2a. NSE served as a loading control. (SN - substantia nigra; OlfB olfactory bulbs; Str - striatum; Hipp - hippocampus; Ctx - cortex; Crb - cerebellum; BS - brainstem; SC spinal cord). E, The intensity of the immunoreactive band of Lamp-2a was quantified by near infrared
densitometry relative to the intensity of neuron specific enolase (NSE). The resulting values were
adjusted proportionally to the value of the hippocampus to normalize intensity across experiments.
Lamp-2a is expressed most prominently in the brainstem and the spinal cord (n=3) (***p<0.001, SC or
BS vs SN, OlfB, Str,Hipp, Ctx, or Crb, one way ANOVA with Tukey’s post-hoc test).
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To determine whether differences in Lamp-2a expression exist across brain
regions, the levels of the 72kDa Lamp-2a band were compared across eight different
brain regions (Figure 2-1D). The brains of non-transgenic mice were used for this
investigation in order to decipher inherent regional differences independent of transgene
effects. Lamp-2a showed increased expression in the brainstem and spinal cord, the two
regions that develop the most extensive inclusions in the A53T α-syn transgenic mice
(Figure 2-1E).
Lamp-2a expression is upregulated selectively in the inclusion-forming regions upon
the onset of motor symptoms in A53T α-synuclein transgenic mice.
In A53T α-syn transgenic mice, α-syn aggregation occurs most prominently in the
brainstem and the spinal cord (Giasson et al., 2002; Tsika et al. 2010). Therefore, the
enhanced expression of Lamp-2a in these regions was counterintuitive, as that would
seemingly provide those areas with enhanced protein clearance. Consequently, it was
important to examine the effects of both A53T α-syn transgene expression and disease
onset on the expression of this protein. Four groups of mice were studied; A53T α-syn
mice that had developed motor symptoms, age-matched A53T α-syn mice that had not
yet developed symptoms, age-matched non-transgenic mice, and young A53T α-syn mice
(2.5 months of age). These mice were examined across two regions; the hippocampus, a
region that develops minimal α-syn inclusions, and the spinal cord, a region that develops
robust α-syn inclusions in A53T α-syn mice. Neither age nor transgene expression
affected the overall levels of Lamp-2a within each respective region. However, upon the
onset of motor symptoms, there was a selective increase in Lamp-2a in the spinal cord
(Figure 2-2A, B).
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To determine whether this increase in levels of the Lamp-2a protein were due to
differences in mRNA, levels of Lamp-2a mRNA were quantified for the same conditions
of mice. For this analysis, a primer against the C-terminal region of Lamp-2a was used
that is specific to Lamp-2a and not the other Lamp-2 isoforms. Similar to the protein
expression, levels of Lamp-2a mRNA were not affected by transgene expression or age
within a particular region (Figure 2-2C). However, in the spinal cord there was a greater
than two-fold increase in the levels of Lamp-2a mRNA in the symptomatic mice
compared to the other conditions (Figure 2-2C). When the levels of Lamp-2a mRNA in
the spinal cord were compared relative to the levels in the hippocampus of the same
mouse for each of the four groups, the spinal cord of the symptomatic mouse had nearly
eight-fold greater levels of Lamp-2a mRNA than the hippocampus (Figure 2-2D). These
changes in mRNA and protein levels indicate a distinct recognition and response of the
CMA system to the stress of α-syn aggregation.
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Figure 2-2. Increased levels of Lamp-2a in the spinal cord during the onset of symptoms in
transgenic A53T α-syn mice. A, The hippocampus (Hipp) and the spinal cord (SC) from
symptomatic A53T α-syn transgenic mice (sympt), age matched non-symptomatic A53T α-syn
transgenic mice (non-sympt), age matched non-transgenic mice (nonTg), and young A53T α-syn
transgenic mice (2.5 months of age - young) were analyzed by SDS-PAGE/western blot for Lamp2a. NSE was used as a loading control. B, The intensity of the immunoreactive band of Lamp-2a
was quantified by densitometry relative to the intensity of NSE. The resulting values were adjusted
proportionally to the value of the non-transgenic spinal cord to normalize intensity across
experiments. This reinforced the increased levels of lamp-2a in the spinal cord relative to the
hippocampus but revealed no effect of age or transgene expression on expression. Upon the onset of
symptoms there was a selective increase in Lamp-2a in the spinal cord (n=3) (**p<0.01, ***p<0.001,
Levels of Lamp-2a in SC versus Hipp within a particular condition of mice; ‡‡ p<0.001, Levels of
Lamp-2a in the symptomatic SC versus non-Tg SC, young SC, and non-symptomatic SC, one-way
ANOVA with Tukey’s post-hoc test). C, Quantitative PCR with a primer against Lamp-2a and a
primer against NSE as a control was performed on cDNA synthesized from RNA extracted from
same conditions described above. Levels of Lamp-2a mRNA within the hippocampus and spinal
cord were held relative to values for the non-transgenic mouse in each region. Comparison across
the groups of mice revealed no change in mRNA levels in the hippocampus, but in the spinal cord
there was a significant increase in Lamp-2a mRNA in the symptomatic A53T α-syn transgenic mice
relative to the other conditions (n=3) (*** p<0.001, sympt SC versus non-Tg SC, young SC, and
non-sympt SC, one-way ANOVA with Tukey’s post-hoc test). D, Levels of Lamp-2a mRNA in the
spinal cord were held relative to the levels in the hippocampus of the same mouse. This revealed a
significant increase in expression in the spinal cord compared to the hippocampus of the
symptomatic A53T α-syn transgenic mice (n=3) (* p<0.05, SC versus Hipp, paired t-test).
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Deficiencies in CMA-independent autophagic proteins in the spinal cord relative to
the hippocampus.
While this data reinforces the relationship between α-syn and CMA, it is unclear
how the regions that have both the highest level of endogenous Lamp-2a expression as
well as the ability to dynamically upregulate these levels in response to altered substrate
homeostasis are ultimately the most vulnerable to protein aggregation. Therefore, the
expression of another component of CMA as well as a general lysosomal protein and a
marker of macroautophagy were explored. The levels of Hsc70, the CMA chaperone, did
not change across regions or upon symptom development (Figure 2-3A). However,
examination the mature form of Cathepsin D revealed decreased levels of this lysosomal
protease in the spinal cord relative to the hippocampus (Figure 2-3B). These levels were
not affected by symptom development, but suggest that there may be decreased
lysosomal capacity either in the number of lysosomes or the number of hydrolases per
lysosome in the spinal cord relative to the hippocampus. The ratio of LC3-II to LC3-I, a
marker for the induction of macroautophagy, also showed a decrease in the spinal cord
relative to the hippocampus that was not affected by symptom development (Figure 23C). These two proteins demonstrate expression patterns opposite that of Lamp-2a and
are decreased in the regions that are vulnerable to developing α-syn inclusions.
Therefore, it is possible that additional lysosomal deficiencies independent of CMA exist
in the regions that develop pathology and contribute to aggregate formation.

This

apparent insufficiency of other lysosomal systems within the spinal cord reinforces the
importance of CMA within this region. Therefore, it was important to explore whether
the upregulation of Lamp-2a has functional effects. This would decipher the contribution
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of CMA to neurodegeneration and determine whether this selective cellular response is a
sufficient compensatory action that can properly degrade α-syn despite insufficiencies of
other lysosomal components.

Figure 2-3. Deficiencies
in non-CMA lysosomal
components exist in the
spinal cord relative to
the hippocampus. A,
The hippocampus (Hipp)
and the spinal cord (SC)
from symptomatic A53T
α-syn transgenic mice
(sympt), age matched
non-symptomatic A53T
α-syn transgenic mice
(non-sympt),
age
matched non-transgenic
mice (nonTg), and young
A53T α-syn transgenic
mice were analyzed by
SDS-PAGE/western blot
for Hsc70. NSE was
used as a loading control.
The intensity of Hsc70
bands were quantified by
densitometry relative to
the intensity of NSE. No
significant
differences
were
found
across
conditions (n=3).
B,
Analysis of the tissue
from (A) by western blot
for Cathepsin D. The
intensity of Cathepsin D
bands were quantified by
densitometry relative to
the intensity of NSE.
Decreased levels of Cathepsin D are present in the spinal cord relative to the hippocampus across all
conditions of mice (n=3). C, Analysis of the tissue from (A) by western blot for LC3. The intensity of
LC3-II bands were divided by the intensity of bands of LC3-I and held relative to the intensity of NSE.
Decreased levels of LC3-II/LC3-I are present in the spinal cord relative to the hippocampus across all
conditions of mice (n=3). For the quantification of all three antibodies, the resulting values were held
relative to the value of the young hippocampus to normalize across experiments (*p<0.05, **p<0.01, SC
versus Hipp, paired t-test).
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CMA substrates display impaired association with lysosomes.
The next series of investigations focused on examining the functionality of Lamp2a as a receptor; specifically the ability of Lamp-2a to localize to lysosomes and bind and
degrade CMA substrates. The established relationship between Lamp-2a levels and
CMA activity is dependent upon proper targeting of the receptor to the lysosomal
membrane (Cuervo and Dice, 2000a,b). To determine if the differences in overall Lamp2a expression correspond to an analogous pattern of the levels of Lamp-2a at the
lysosomal membrane, lysosomes were extracted from the cortex (another region with
minimal α-syn pathology) and brainstem (another region that develops prominent
inclusions) of the various conditions of mice. The lysosome membranes were then
separated from the lysosomal lumen following bursting of the lysosomes by hypotonic
shock.

Western blot for Lamp-2a revealed that Lamp-2a was associated with the

lysosomal membrane with a similar expression pattern to that of the whole cell
homogenate (Figure 2-4A). This establishes that cellular upregulation of Lamp-2a is
reflected in corresponding changes in Lamp-2a levels at the lysosomal membrane and
that the Lamp-2a in these regions is not mislocalized or confined to the lysosomal lumen.
To further examine the lysosomal dynamics within these brain regions, the
association of CMA substrates with lysosomes from the cortex and brainstem was
examined. Lysosomes were extracted from the cortex and brainstem of symptomatic,
non-symptomatic, young, and non-transgenic mice. Lysosomal enrichment was verified
with an antibody against the lysosomal protease Cathepsin D (Figure 2-4B). The amount
of GAPDH, an established CMA substrate, or α-syn associated with the lysosome was
then evaluated. The number of micrograms of lysosomes in each condition was held
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constant, preventing the effect of any possible discrepancy in lysosomal quantity across
various regions. Interestingly, α-syn showed decreased association with lysosomes in the
brainstem relative to the cortex (Figure 2-4C,D). This did not change upon symptom
development. However, GAPDH showed an equal amount of association across the
various regions (Figure 2-4C). Therefore the higher levels of Lamp2a in lysosomal
membrane do not correspond to increased substrate binding. Levels of Lamp-2a at the
lysosomal membrane have been described as the rate-limiting step in the lysosomal
binding, uptake, and degradation of CMA substrates (Cuervo and Dice, 2000a,b).
Consequently, the levels of Lamp-2a, not the levels of substrate available, should
determine the amount of substrate associated with the lysosomes. However, the levels of
α-syn associated with lysosomes proportional to the total expression of α-syn in the
whole homogenate was equivalent across the regions (Figure 2-4E). This suggests that
lysosomal association of a-syn is not proportional to the levels of Lamp-2a but is
influenced by the overall levels of substrate present in the cell. Levels of GAPDH
associated with lysosomes remained equal across the regions when adjusted to the total
level of GAPDH in the cell (Figure 2-4F).
Examination of the levels of other proteins associated with isolated lysosomes
revealed that lysosomal levels of Hsc70 did not change across conditions (Figure 2-4C).
Therefore, any impairment in substrate binding is not due to deficits in the CMA
chaperone. Additionally, levels of Cathepsin D in isolated lysosomes did not vary across
brain regions, indicating that the expression differences seen in whole homogenate are
due to different amounts of lysosomes in each region rather than different concentrations
of proteases within each lysosome (Figure 2-4B).
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Figure 2-4. Association of
substrates with lysosomes
is not proportional to the
levels of Lamp-2a at the
lysosomal membrane. A,
Lamp-2a is localized in
lysosomal
membranes.
Crude lysosomal extract
(light M+L fraction) was
obtained from the cortex or
brainstem of symptomatic
A53T α-syn transgenic mice,
age
matched
nonsymptomatic A53T α-syn
transgenic
mice,
age
matched
non-transgenic
mice, and 2.5 months of age
(young)
A53T
α-syn
transgenic mice. Lysosomes
were burst by hypotonic
shock and the membranes
were separated from the
lumen by ultracentrifugation.
The lysosomal membranes
were analyzed by SDSPAGE/western
blot
for
Lamp-2a.
B,
Crude
lysosomal extracts (light
M+L fraction) were obtained
from the cortex (Ctx) and the
brainstem
(BS)
of
symptomatic A53T α-syn
transgenic mice, age matched non-symptomatic A53T α-syn transgenic mice, age matched non-transgenic
mice, and 2.5 months of age (young) A53T α-syn transgenic mice. The extracted lysosomes were
analyzed by SDS-PAGE/western blot alongside non-fractionated homogenate from the whole brains of
non-transgenic mice with an antibody against Cathepsin D. C, Crude lysosomal extracts (light M+L
fraction) from the conditions described in (B) were analyzed by SDS-PAGE/western blot with antibodies
against human α-syn, GAPDH, and Hsc70. D, Intensity of α-syn immunoreactive bands were quantified
by densitometry. No band for α-syn was present in the non-transgenic mouse, showing that the band is
specific for transgenic A53T human α-syn, and was excluded from the report of densitometric analysis.
α-Syn showed decreased association with lysosomes in the brainstem relative to the cortex (n=4)
(*p<0.05, **p<0.01, BS versus Ctx, paired t-test).. E, The corresponding cytoplasmic fraction that
remained after lysosome extraction from each sample was also analyzed by SDS-PAGE/western blot for
α-syn and quantified by densitometry. NSE was used as a loading control for the cytoplasmic fraction.
The intensity of the bands of α-syn associated with the extracted lysosomes were reported as a value
relative to the intensity of the total cellular level of α-syn (intensity of the band for the cytoplasmic
fraction (normalized to NSE) combined with the intensity of the band in the lysosomal fraction). No
significant differences were found across conditions (n=4).
F, Extracted lysosomes and the
corresponding cytoplasmic fractions were analyzed as in (D) with an antibody against GAPDH. No
significant differences were found across conditions (n=4).

60

Lysosomes from pathogenic regions show decreased uptake and degradation of
CMA substrates.
The incongruence between Lamp-2a levels and lysosomal substrate binding
prompted investigation of CMA function in lysosomes from these different brain regions.
To test this, a lysosomal activity assay was performed. From non-transgenic mice,
purified lysosomes were extracted from the brainstem and spinal cord, regions that are
vulnerable to developing α-syn aggregates, or from the remaining brain regions that are
less prone to developing pathology. The use of non-transgenic mice prevented any
confounding effects from existing associations between A53T α-syn and the lysosomes.
The absence of mitochondrial proteins in these lysosomal extracts was verified by
western blot (Figure 2-5A). These purified lysosomes were then incubated at 37 °C with
a mixture that included an energy-regenerating system containing ATP, the Hsc70
chaperone, and exogenous purified human α-syn. The amount of α-syn remaining was
then determined by quantitative western blot with an antibody specific to human α-syn.
A condition of burst lysosomes from each of the two regional groups was included as a
control for the protease ability of the lysosomes. The lysosomes from the brainstem and
spinal cord (Path) had a significantly decreased ability to degrade exogenous wild-type αsyn compared to the remainder of the brain (Non-Path) (Figure 2-5B). This effect was
dependent upon the addition of ATP and Hsc70, as has been characterized for CMA
substrates (Chiang et al., 1989; Cuervo et al., 1994). Additionally, incubation of the
lysosomes at 4 °C, which prevents uptake, negated this difference in α-syn degradation
(Figure 2-5B).

The previously described deficiency in substrate binding was not
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responsible for the regional differences because equal quantities of exogenous α-syn were
added to lysosomes from the two regions.
Investigations next focused on the ability of lysosomes to take up and degrade
endogenous substrates.

Following extraction of lysosomes, bound CMA substrates

remain associated with the lysosomes. The rate up uptake and degradation of these
substrates can then be determined by monitoring the amount of remaining protein in the
isolated system at varying lengths of time. Lysosomes were obtained as described as
above, and incubated with an energy regenerating system containing ATP. Levels of the
CMA substrate GAPDH were monitored at different time points by quantitative western
blot. The number of micrograms of lysosomes in each condition was held constant,
preventing the effect of any possible discrepancy in lysosomal quantity across various
regions.

Similar to the assay involving exogenous addition of α-syn, endogenous

GAPDH showed impaired uptake and degradation in the pathogenic regions of nontransgenic mice (Figure 2-5C). This effect was dependent on the presence of ATP and on
lysosomal uptake, as determined by conditions lacking the energy regenerating system or
incubated at 4 °C (Figure 2-5C). However, in symptomatic A53T α-syn mice, the levels
of GAPDH degradation were similar in the pathogenic and non-pathogenic regions
(Figure 2-5D). The rate of GAPDH degradation was calculated for the pathogenic and
non-pathogenic regions of the non-transgenic and symptomatic A53T mice.

This

degradation rate was then normalized to the levels of Lamp-2a in these regions. Because
the number of micrograms of lysosomes was held constant across the different
conditions, the resulting values were not influenced by different numbers of lysosomes in
the various regions. This data revealed that while the rate of GAPDH degradation
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increased in the pathogenic regions of the symptomatic mice, this increase was
proportional to the increase in Lamp-2a expression (Figure 2-5E). Therefore, the rate of
degradation relative to levels of Lamp-2a protein remained constant (Figure 2-5E).
However, the non-pathogenic regions had a much greater rate of protein degradation
relative to the levels of Lamp-2a expression compared with the pathogenic regions
(Figure 2-5E). Therefore, there is a regionally selective insufficiency in CMA substrate
uptake and degradation in the regions that are most prone to developing inclusions.
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Figure 2-5. Lysosomes from the regions of the brain that
are most vulnerable to α-syn inclusions demonstrate
reduced CMA activity in their ability to take up and
degrade substrates.
A,
Purified lysosomes were
extracted from the regions
of the brainstem and spinal
cord that are vulnerable to
developing
pathology
(“Path”) or the remainder of
the brain (“Non-Path”) of
non-transgenic mice. The
purified lysosomal fractions were
verified to be free of mitochondria by
SDS-PAGE/western blot with the
mitochondrial marker cytochrome c
oxidase I (MTCO1). B, Purified
lysosomes (25 µg) were incubated
with 0.2 µg of purified human α-syn
with Hsc70 and an energy
regenerating system at 37 °C. After
the incubation, the samples were
analyzed by SDS-PAGE/western blot
with a human specific α-syn antibody
and quantified by densitometry.
Lysosomes (25 µg) burst by
hypotonic shock were also incubated
with 0.2 µg of α-syn under the same
conditions as a control. To control
for CMA dependent uptake, a “No
ATP/Hsc70” condition was included
where neither the ATP energy
regenerating system nor Hsc70 were
included.
An additional control
condition involved incubation of the
lysosomes at 4 °C during the reaction
to prevent uptake. All values were
held relative to a final condition in
which the 0.2 µg of α-syn was
incubated under the same conditions without lysosomes. The brainstem and spinal cord have a decreased
ability to degrade α-syn by CMA, a difference that is not due to any deficiencies in the degradation ability of
the lysosomal proteases and is dependent on ATP and lysosomal uptake(**p<0.01 path versus non-path
regions, t-test, intact lysosomes (n=10), all other conditions, (n=3)). C, To determine the degradation of
GAPDH endogenously associated with lysosomes, 75ug lysosomes were purified from non-transgenic mice.
The lysosomes were then incubated for the indicated time points at 37° C with an energy regenerating system.
After the incubation, the samples were analyzed by SDS-PAGE/western blot with a GAPDH antibody and
quantified by densitometry. As a control for CMA dependent uptake, a “No ERS” condition was included
where the ATP energy regenerating system was not included. An additional control condition involved
incubation of the lysosomes at 4 °C during the reaction to prevent uptake. All values were held relative to a
condition in which the lysosomes were immediately frozen. The pathogenic regions of non-transgenic mice
have a decreased ability to degrade endogenous GAPDH by CMA, a difference that is dependent on ATP and
lysosomal uptake (n=3, ***p<0.001, Non-Path vs Path for each timepoint, one-way ANOVA with Tukey’s
post-hoc test). D, The endogenous lysosomal degradation of GAPDH was assessed for symptomatic A53T+/+
α-synuclein mice as in (C). The pathogenic regions of the A53T α-synuclein mice display comparable
degradation of endogenous GAPDH compared to the non-pathogenic regions (n=3). E, The rate of GAPDH
degradation was determined by comparing the intensity of the bands of the 0 hr and 15 hr time points in (C)
and (D) with known standards of purified GAPDH. The resulting values were then divided by the relative
amounts of Lamp-2a present in the different conditions, as determined by western blot (n=3).
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2.5 Discussion
Three different autosomal dominant mutations in the gene encoding α-syn as well
as duplication or triplication of the α-syn gene have been linked with familial forms of
PD (Polymeropoulos et al., 1997; Kruger et al., 1998; Chartier-Harlin et al., 2004;
Zarranz et al., 2004). Additionally, wild type α-syn is a component of the Lewy Body
inclusions found in the degenerating brain regions of patients with sporadic PD,
supporting a role for this protein in disease (Spillantini et al., 1997).

Despite

considerable advances in understanding the physiological and pathological roles of α-syn,
it is unclear why α-syn forms inclusions only in select brain regions despite relatively
uniform expression. While catastrophic failure of protein clearance permits proteins with
amyloid forming capacity to aggregate and form inclusions, it is not known how these
degradation systems may contribute to regionally selective aggregation. Previous studies
in vitro or in cell models have indicated that α-syn modified with the A53T mutation or
modified by oxidized dopamine can impair CMA uptake and degradation by binding
strongly to Lamp-2a and blocking the receptor (Cuervo et al., 2004; Martinez-Vicente et
al., 2008). While it is possible that this process also occurs within the brain, it does not
explain why certain brain regions are vulnerable to α-syn inclusion formation and cellular
dysfunction while others are spared. Therefore, the present study employed a mouse
model to identify regional differences in the CMA pathway that may explain selective αsyn aggregation.
In the mouse brain, Lamp-2a has an apparent molecular weight of 72kDa as
determined by the absence of this band in western blots with Lamp-2 knockout mice and
confirmed by mass spectrometry. Lamp-2a has previously been described as a 96kDa
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protein in the mouse liver (Cuervo and Dice, 1996). Lamp-2a is one of the most highly
glycosylated proteins in the cell.

It is decorated with 4 O-linked and 16 N-linked

glycans, the majority of which are complex oligosaccharides, particularly poly-Nacetyllactoasmines (Carlsson et al., 1988; Carlsson et al., 1990; Carlsson et al., 1993).
These glycans are critical for protecting the protein from degradation by the proteases in
the lysosomal lumen. Removal of the N-linked glycans has been shown to result in rapid
degradation of Lamp-2 (Barriocanal et al., 1986; Kundra et al., 1999). This unique
72kDa molecular weight appears to be due to differential glycosylation of the protein.
The brainstem and spinal cord are the two brain regions that develop the most
prominent inclusions in A53T α-syn transgenic mice. Examining the brains of nontransgenic mice for inherent regional differences that could explain this selective
vulnerability revealed increased levels of Lamp-2a in the brainstem and the spinal cord
compared to other brain regions. Given the unique composition of neural cell types in
each brain region, further investigations are needed to determine whether this discrepancy
in expression levels is due to the specific contributions of particular types of cells.
Interestingly, upon the onset of motor symptoms in the A53T transgenic mice, a dramatic
increase in the levels of Lamp-2a mRNA and protein occurs. This response reinforces
the critical role of CMA in the regulation of α-syn homeostasis. While Lamp-2a acts as
the modulator of CMA activity during a variety of cell stress conditions, the method by
which the levels Lamp-2a in the lysosomal membrane are increased varies depending on
the insult. Starvation does not induce the synthesis of new Lamp-2a but rather recruits
already formed Lamp-2a from the lysosomal lumen to the lysosomal membrane (Cuervo
and Dice, 2000a). Alternately, oxidative stress stimulates transcriptional upregulation of
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Lamp-2a (Kiffin et al., 2004; Mak et al., 2010). The present study reports a novel
response of Lamp-2a that is sensitive to dynamic changes in cellular protein homoestasis.
However, both the pattern of Lamp-2a expression as well as the apparent responsiveness
of the system does not predict a vulnerability of the brainstem and spinal cord to α-syn
aggregation. Therefore, other potential factors were explored.
Levels of the CMA chaperone Hsc70 did not change across regions or symptom
development. Therefore, the differences seen with Lamp-2a are not generalized to all
CMA components. However, levels of the lysosomal protease Cathepsin D, and the
levels of LC3-II/LC3-I, an autophagosome marker, were both decreased in the spinal
cord relative to the hippocampus. When Cathepsin D levels were examined in equal
amounts of isolated lysosomes, no differences in expression were seen across brain
regions.

Therefore, it appears that there are decreased numbers of lysosomes and

decreased induction of macroautophagy in the spinal cord relative to the hippocampus.
The increased levels of Lamp-2a seen in the spinal cord in basal conditions may represent
an attempt to compensate for the other lysosomal deficiencies, as CMA activity has been
shown to be upregulated upon the inhibition of macroautophagy (Kaushik et al., 2008).
This lysosome deficiency would leave the spinal cord prone to α-syn aggregation.
However, since α-syn is a CMA substrate, investigations next focused on determining
whether the upregulation of Lamp-2a is able to effectively compensate for other
lysosomal insufficiencies and properly clear α-syn.
To assess CMA function across brain regions and symptom onset, the ability of
lysosomes to bind CMA substrates was first examined. This revealed that the levels of
substrates associated with lysosomes was not proportional to Lamp-2a levels but was
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instead proportional to the overall levels of substrate present in the cell. Consequently,
Lamp-2a upregulation is unable to effectively increase association of CMA substrates
with lysosomes.
An additional level of lysosomal deficiency appears to be present at the level of
CMA substrate uptake and degradation.

With isolated lysosomes, CMA-mediated

lysosomal degradation can be measured directly, since macroautophagy is negated by the
lack of autophagosome formation.

Isolated lysosomes were either assayed for

degradation of exogenously added wild-type α-syn or monitored for the degradation of
the endogenous GAPDH associated with the extracted lysosomes. In both cases, the
lysosomes from the pathogenic regions of non-transgenic mice exhibited decreased
ability to take up and degrade substrates. The decrease in substrate degradation is not due
to the altered kinetics of substrate association since levels of substrates were equal across
the pathogenic and non-pathogenic regions. However, in symptomatic A53T α-syn mice,
the pathogenic regions displayed degradation rates comparable to the non-pathogenic
regions. This increase in degradation was proportional to the increased levels of Lamp2a expression that occur upon symptom onset, indicating that in the pathogenic regions,
Lamp-2a mediates CMA activity. However, the difference in degradation rates across
brain regions was not correlated with the levels of Lamp-2a receptor. This indicates that
a Lamp-2a independent mechanism accounts for the regional differences in protein
degradation. One possible explanation for this discrepancy is that additional factors may
contribute to direct lysosomal uptake. In addition to Lamp-2a, an additional receptor or
chaperone may promote increased degradation in the regions that are less vulnerable to
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developing inclusions. Further studies must be performed to decipher these various
possibilities.
Previous studies in vitro demonstrated that A53T α-synuclein impairs CMA
degradation by blocking the Lamp-2a receptor (Cuervo et al., 2004). However, the
present data indicates that in vivo, the rate of CMA degradation is not impaired by
expression of A53T α-synuclein, even in the presence of α-synuclein aggregates. While
the upregulation of Lamp-2a expression in the pathogenic regions upon the onset of
motor symptoms is able to increase lysosomal degradation to a rate comparable to the
non-pathogenic regions, this is unlikely to reverse the onset of disease. At the onset of
motor symptoms, the presence of α-synuclein aggregates is already apparent. Because
substrates must be unfolded to pass through the Lamp-2a receptor, CMA is unable to
degrade oligomers or aggregates (Salvador et al., 2000; Martinez-Vicente et al., 2008).
In summary, this study provides insight into the role of CMA in disease in an in
vivo context. Inherent lysosomal differences were found across brain regions of nontransgenic mice and in mice expressing human A53T α-syn. Based on these data we
propose that multiple lysosomal deficiencies contribute to regional selectivity of α-syn
neurodegeneration. The initial insult comes from decreased lysosomal capacity in the
regions vulnerable to α-syn inclusion formation. Potentially as compensation, there is an
attempt at upregulation of the CMA receptor Lamp-2a receptor in these regions,
particularly upon the onset of disease. However, the upregulation of Lamp-2a levels does
not increase the ability to bind and remove α-syn.

Overall the data revealed that

multifactorial lysosomal dysregulation may provide a potential mechanism for the
regional selectivity of α-syn inclusion formation and neurodegeneration.
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CHAPTER 3
Investigation of the selective vulnerability of α-synuclein to aggregation
during proteolytic dysfunction.

By:
Kristen A Malkus, Matthew Figley, and Harry Ischiropoulos

Acknowledgements : This work was supported by NIH grants AG13966 and ES013508
NIEHS Center of Excellence in Environmental Toxicology. HI is the Gisela and Dennis
Alter Chair in Pediatric Neonatology at the Children's Hospital of Philadelphia. We
thank Dr. Benoit Giasson for the human brain tissue and Richard Lightfoot for the
purified human α-synuclein.

70

3.1 Abstract
The formation of α-synuclein oligomers and aggregates has been implicated in the
pathogenesis of Parkinson’s disease (PD) and related disorders. Recent data suggests that
impairments in protein degradation pathways, including chaperone mediated autophagy
(CMA), contribute to accumulation of α-synuclein and consequent formation of
multimers.

However, it remains unclear how generalized disruption of protein

degradation results in the selective aggregation of a particular protein. The present study
explores possible factors that contribute to the selective vulnerability of α-synuclein to
protein degradation dysfunction. Three possibilities were explored. First, the ability of
the CMA chaperone Hsc70 to recognize α-synuclein as a substrate for degradation was
investigated. Next, the native state of soluble α-synuclein was characterized to determine
whether α-synuclein non-covalently associates with itself or other proteins in soluble
complexes. Such associations could impede the unfolding and uptake of α-synuclein into
the lysosome for degradation. Finally, the possible contribution of lipid metabolism was
investigated. The CMA receptor Lamp-2 contributes to cholesterol turnover, and lipids
have been shown to promote the aggregation of α-synuclein. Consequently, impaired
Lamp-2a activity could lead to an accumulation of both lipids and α-synuclein and
exacerbate the formation of aggregates. The data revealed that soluble α-synuclein does
not exhibit deficits in CMA substrate recognition and is present as a soluble unfolded
monomer in vivo.

However, differences were observed in components of lipid

metabolism in regions that are vulnerable to developing α-synuclein inclusions compared
to regions that develop minimal inclusions. Levels of ApoE were decreased in the
inclusion-forming regions, while levels of LDLR were increased, suggesting that lower
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levels of lipids are present. Therefore, regional alterations in lipid metabolism may serve
as a modulating factor to selectively promote the aggregation of α-synuclein.
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3.2 Introduction
The protein inclusions that characterize many neurodegenerative diseases are
composed of a large array of cellular proteins (Leverenz et al., 2007; Xia et al., 2008).
However, select proteins appear to be particularly vulnerable to misfolding and
aggregation and likely seed the formation of these aggregates. α-Synuclein is a protein
whose aggregation is affiliated with several neurodegenerative diseases, including
Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system
atrophy (MSA) (Spillantini et al., 1997; Polymeropoulos et al., 1997; Kruger et al., 1998;
Chartier-Harlin et al., 2004; Zarranz et al., 2004).
Impairments in protein degradation have been shown to promote the aggregation
of α-synuclein (Stefanis et al, 2001; Paxinou et al., 2001, Webb et al., 2003). One
pathway that participates in the degradation of α-synuclein is chaperone mediated
autophagy (CMA), a selective route of direct lysosomal substrate uptake (Cuervo et al.,
2004; Vogiatzi et al., 2008; Mak et al., 2010). Using a mouse model of synucleinopathy,
we have demonstrated that there is impaired CMA activity selectively in the regions
vulnerable to inclusion formation (Chapter 2). This dysfunction provides a potential
mechanism for the accumulation of substrates and promotion of aggregate formation.
However, approximately thirty percent of cytosolic proteins contain the pentapeptide
motif that targets proteins for CMA and are consequently potential CMA substrates
(Chiang and Dice, 1988).

Therefore, it is unclear why, during times of CMA

dysfunction, α-synuclein is selectively vulnerable to aggregation.
In CMA, substrates must first be unfolded in order to pass through the Lamp-2a
receptor into the lysosome for degradation (Salvador N et al., 2000). Oligomeric α73

synuclein is able to bind to the lysosomal membrane, but is unable to be unfolded or
taken up into lysosomes (Martinez-Vicente et al., 2008). Therefore, once the process of
aggregation has begun, it is evident that CMA is insufficient for clearing α-synuclein.
However, a preceding factor still must make α-synuclein initially susceptible to
oligomerization.

One possibility is impaired recognition of α-syunclein as a CMA

substrate. The chaperone heat shock cognate protein of 70kDa (Hsc70) is responsible for
the recognizing CMA substrates and transporting them to the lysosome for degradation
(Chiang et al., 1989; Terleckey et al., 1992). Deficiencies in the ability of Hsc70 to
identify and translocate α-synuclein would lead to its selective accumulation and promote
aggregation.
Additionally, it is possible that once α-synuclein has been transported to the
lysosome, structural properties of the protein prevent its efficient uptake and degradation.
α-Synuclein has been extensively characterized both in vitro and in vivo. Initial studies in
vitro have described α-synuclein as a natively unfolded monomer using an array of
techniques including sedimentation coefficients, gel filtration, circular dichromism,
Fourier transform infrared spectroscopy, and nuclear magnetic resonance spectroscopy
(Weinreb et al., 1996; Eliezer D, 2001).

However, due to the association of the

aggregated form of the protein with disease, the majority of research has focused on
characterizing the insoluble α-synuclein found in inclusions. Studies in vivo consistently
use denaturing techniques to examine the biochemical properties of this protein (Paxinou
et al., 2001; Mazzulli et al., 2006; Giasson et al., 2002; Tsika et al., 2010; Baba et al.,
1998; Lippa et al., 1998; Giasson et al., 2000). Consequently, the native soluble state of
α-synuclein has not been fully explored in vivo.
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The formation of non-covalent

oligomeric species or complexes with other proteins could impede the unfolding, uptake,
and degradation of α-synuclein by CMA.
α-Synuclein may also be selectively affected by other cellular components that
promote its aggregation.

Lipids have been shown to modulate both α-synuclein

aggregation and CMA function.

The N terminus of α-synuclein contains a series of

eleven-residue repeats that allow α-synuclein to bind to phospholipids or synthetic lipid
membranes and promote formation of an α-helical conformation (Davidson et al., 1998;
Jo et al., 2000; Cole et al., 2002). Additionally, α-synuclein is able to associate with
polyunsaturated fatty acids (PUFAs) which promote the formation of multimers (Perrin et
al., 2001; Sharron et al., 2003a). PUFA levels are increased in the brains of patients with
PD and DLB (Sharon et al., 2003b) and Lewy bodies purified from PD brains contain
lipids (Gai et al., 2000). Furthermore, application of cholesterol-lowering drugs to both
cells and mice has been shown to decrease α-synuclein aggregation (Bar-On et al., 2006,
2008; Koob et al., 2010). The CMA receptor Lamp-2a is involved in lipid metabolism,
with knockout of Lamp-2a resulting in accumulation of unesterified cholesterol in
lysosomes (Eskelinen et al., 2004; Schneede et al., 2009). Conversely, lipid levels also
affect CMA activity. At rest, the Lamp-2a receptor is localized in lipid microdomains in
the lysosomal membrane. However, in order to transport substrates into the lysosomes,
Lamp-2a must exit these lipid-rich regions and multimerize (Kaushik et al., 2006).
Cholesterol-depleting agents increase CMA activity, while addition of cholesterol to cell
culture medium decreased CMA activity in those cells (Kaushik et al., 2006).
In the present study, various factors that potentially contribute to the initiation of
α-synuclein aggregation were explored. First, the ability of the CMA chaperone Hsc70 to
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recognize α-synuclein across different brain regions and upon the onset of disease was
investigated. Studies next focused on the native soluble state of α-synuclein in both the
mouse and human brain. Finally, several components of lipid metabolism were measured
across regions to decipher a contribution to the selective vulnerability of α-synuclein to
aggregation in certain parts of the brain.

3.3 Materials and Methods
Mouse breeding. The mice used in this study express human A53T α-syn (line M83)
driven by the murine PrP promoter (Jackson Laboratory, Bar Harbor, Maine) and have
been described previously (Giasson et al., 2002).

To generate the A53T+/+ and

nontransgenic (nonTg) mice used in experiments, heterozygous A53T+/- females were
mated with A53T+/- males. Genotyping was performed by both end-point PCR using
GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, Carlsbad, CA) and
quantitative PCR using Applied Biosystems 7500 real-time PCR System with the ABI
MGB primer-probe set for human SNCA, the gene that encodes α-syn (Applied
Biosystems assay ID Hs00240907_m1). SNCA values were normalized to mouse β-actin
(Applied Biosystems assay ID 4352341E).
Mouse organ dissection for biochemical analysis. For analysis of brain regions, mice
were anaesthetized with CO2 followed by cervical dislocation. The brain and spinal cord
were dissected and rinsed thoroughly with ice-cold phosphate buffered saline (PBS). The
brain was submerged in ice-cold PBS and sliced into 1 mm thick coronal sections using a
vibratome and the hippocampus was dissected away (World Precision Instruments,
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Sarasota, FL). Dissected brain regions were weighed, rapidly frozen on dry ice, and
stored at -80°C until analysis
Western Blotting. Brain tissue was homogenized with 10 volumes of lysis buffer [20mM
HEPES (pH7.4), 150mM NaCl, 10% Glycerol, 1% TritonX-100, 1mM EGTA, 1.5mM
MgCl2, 1mM PMSF, 1:50 Protease Inhibitor Cocktail (Sigma P8340)] unless otherwise
indicated. For analysis of α-synuclein molecular weight in human tissue, a glycerol lysis
buffer was used, in which the 1% Triton X-100 was excluded from the recipe above. A
Digitonin lysis buffer was also used in which the 1% Triton X-100 from the recipe above
was replaced with 0.5% Digitonin. The tissues were homogenized with the aid of a
mechanical homogenizer (Fisher Jumbo Stirrer 14-501) and then subjected to four
consecutive freeze and thaw cycles of 2 min each (-80°C ethanol bath / 37°C water bath).
The sample was then centrifuged for 30 min at 18,000xg at 4°C. The supernatant was
retained and protein concentration was determined by the microBCA assay (Thermo
Fisher Scientific, Rockford, IL). For denaturation treatment of α-synuclein samples for
native gel analysis, mouse brain was homogenized in the 1% TritonX-100 lysis buffer
described above. Human recombinant α-syn protein used for the assay was expressed
and purified as described previously (Giasson et al., 1999). For the no treatment
condition, samples were incubated on ice for 45 min. Boiling involved boiling the
sample for 10 minutes. For the SDS condition, 1% SDS was added. For the urea
condition, 8M urea was added. For the triton condition, 1% Triton X-100 was added to
the recombinant α-synuclein. Unless otherwise indicated, 50 μg of material was loaded
per lane for analysis by SDS-PAGE or clear native gel electrophoresis followed by
western blot. The tissue was analyzed with the following primary antibodies : 1:1000 α77

syn specific for human α-syn (Syn211, Sigma S5566), 1:10,000 GAPDH (Sigma G9545),
1:500 Hexokinase (Chemicon MAB1534) 1:500 ApoE (Biodesign K23100R), 1:4000
NSE (Polysciences Inc. 16625), 1:300 Lamp-2a (Invitrogen 51-2200) Primary antibodies
were detected with one of the following conjugated secondary antibodies: goat anti-rabbit
IgG IRDye680 (1:5000, Rockland), donkey anti-mouse IgG IRDye800 (1:5000,
Rockland), donkey anti-mouse IgG IRDye680 (1:5000, Rockland) and scanned with the
Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE). The protein bands
from the western blots were quantified by densitometry using Odyssey infrared imaging
system software (Odyssey version 2.1, Li-Cor Biosciences, Lincoln, NE).
Immunoprecipitation. 12ug Hsc70 antibody (Abcam ab2788) were conjugated to 1.5mg
Dynabeads.

The antibody bound beads were then washed

sequentially in sodium

phosphate buffer (pH 7.4), 100mM Glycine HCl (pH 2.5), 10mM Tris (pH 8.8), 100mM
triethylamine, phosphate buffered saline (PBS), 0.1% milk, and 0.5% Triton X-100, and
PBS. 150ug of brain homogenate was then added to the antibody-bound beads and
rocked for 1hr at 4°C. The beads were then washed five times with PBS. The protein
was eluted from the beads with 0.5N NH4OH and 0.5mM EDTA for 20min at room
temperature and analyzed by SDS-PAGE / western blot.

100ug of the non-

immunoprecipitated brain homogenate was retained as input.
Gel Filtration-HPLC. One milligram of TritonX-100 soluble brain tissue in a total
volume of 250 µl was loaded onto a Superdex 200 HR 10/30 column (GE Healthcare
Bio-Sciences, Uppsala, Sweden) connected to an Agilent 1100 HPLC system for size
exclusion chromatography. Protein extracts were resolved at a flow rate of 0.3 ml/min in
25 mM HEPES pH 7.25 and 150 mM NaCl.
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The fractions were collected and

concentrated in 10kDa Amicron Ultra Filters and analyzed by SDS-PAGE or clear native
gel electrophoresis followed by western blot for human α-synuclein.
RNA isolation and RT-PCR. RNA was extracted from the hippocampus and spinal cord
using the TRIzol reagent (Invitrogen, 15596-026), and cDNA was synthesized using the
Superscript II First Strand Synthesis System for RT-PCR (Invitrogen 11904-018).
Quantitative PCR was performed on this cDNA using Applied Biosystems 7500 real-time
PCR System with the ABI MGB primer-probe set for LDLR (Applied Biosystems assay
ID mM01151337_m1). LDLR values were normalized to neuron specific enolase (NSE)
(Applied Biosystems assay ID mM00469062_m1)

3.4 Results
In CMA, proteins containing a five amino acid motif are selectively recognized
by the chaperone heat shock cognate protein of 70kDa.

Hsc70, along with co-

chaperones, transports the substrate to the lysosome where the lysosomal receptor Lamp2a takes up the substrate into the lysosome for degradation (Chiang et al., 1989;
Terleckey et al., 1992; Cuervo and Dice, 1996). Impaired ability of Hsc70 to recognize a
specific substrate such as α-synuclein would promote accumulation and aggregation of
that substrate. Therefore, co-immunoprecipitation assays were performed to examine the
association of α-synuclein with Hsc70.

A mouse model of synucleinopathy that

expresses human A53T α-synuclein was used for this study. The spinal cord, a region
that develops prominent α-synuclein inclusions in these mice, was compared alongside
the hippocampus, a region that develops minimal inclusions. A symptomatic A53T αsynuclein mouse, an age-matched A53T α-synuclein mouse that had not yet developed
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symptoms, and a non-transgenic mouse were examined.

Brain homogenate was

immunoprecipitated with an antibody against Hsc70. The immunoprecipitated material
was then analyzed by western blot for levels of α-synuclein as well as GAPDH, an
established CMA substrate, and hexokinase, a protein known to not be a CMA substrate.
GAPDH did not show any significant difference in association with Hsc70 across regions
or symptom development (Figure 3-1). Using an antibody that selectively recognizes
human α-synuclein, α-synuclein displayed greatly decreased association with Hsc70 in
the spinal cord of the symptomatic mice (Figure 3-1). However, no differences in
association between α-synuclein and Hsc70 were seen in the hippocampus compared to
the spinal cord of the non-symptomatic mouse (Figure 3-1). Therefore, the impaired
association seen in the symptomatic mouse is most likely due to the localization of αsynuclein in aggregates where it cannot be recognized by the chaperone, rather than an
inherent deficiency in the recognition of soluble α-synuclein. To further investigate the
selective initiation of α-synuclein aggregation, factors that would impede the uptake of αsynuclein into the lysosomes were explored next.
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Figure 3-1: α-Synuclein selectively displays decreased association with Hsc70 in the spinal
cord of symptomatic mice. A, Homogenate from the hippocampus (Hipp) and the spinal cord
(SC) from symptomatic A53T α-syn transgenic mice, age matched non-symptomatic A53T α-syn
transgenic mice (non-sympt), and age matched non-transgenic mice (nTg) was immunoprecipitated
with an Hsc70 antibody. The immunoprecipitated material was analyzed by SDS-PAGE / western
blot with an antibody specific for human α-synuclein, as well as GAPDH and hexokinase. B,
SDS-PAGE / western blot of the non-immunoprecipitated homogenate verified that the absence of
α-synuclein associated with Hsc70 was not due to lack of α-synuclein in the input sample.

In order for CMA substrates to be taken up through the Lamp-2a receptor for
degradation, they must first be unfolded. Formation of multimers or stable association
with other proteins would consequently impair α-synuclein’s uptake and degradation.
Therefore, the native in vivo state of α-synuclein was examined. Brain homogenate from
a non-symptomatic A53T α-synuclein mouse was run on an SDS-PAGE gel or a clear
native gel. Western blot for α-synuclein revealed a band with an apparent molecular
weight of approximately 16kDa corresponding to the monomeric protein on the SDSPAGE gel (Figure 3-2A). However, on the clear native gel α-synuclein ran with an
apparent molecular weight 50-60kDa (Figure 3-2A).

Examination of the inclusion

forming regions of the brainstem and spinal cord of a symptomatic A53T α-synuclein
mouse revealed the presence of higher molecular weight oligomeric species on the SDSPAGE gel, with molecular weights corresponding to that of a dimer and tetramer (Figure
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3-2B). On the native gel, these oligomeric species ran at an apparent molecular weight of
approximately 250kDa (Figure 3-2B). Examination of human tissue from a patient with
DLB or a control subject with three different mild extraction buffers revealed a similar
pattern of electrophoretic mobility, with an apparent molecular weight of approximately
16kDa on an SDS-PAGE gel, but a band of 50-60kDa on a clear native gel (Figure 32B). Previously, size exclusion chromatography has determined that, due to its unfolded
nature, monomeric α-synuclein elutes at a volume corresponding 34 Å, which equates to
a globular protein of 57kDa (Weinreb et al., 1996; Tsika et al., 2010). Therefore, further
characterization of the α-synuclein on a native gel was needed to determine whether this
species represented an unfolded monomer or an assembled multimer. In symptomatic
A53T α-synuclein mice, size exclusion chromatography of Triton X-100 soluble
homogenate reveals two main species of eluate. In addition to monomeric α-synuclein
that elutes at 34Å, oligomeric species elute at a larger volume corresponding to 53Å
(Tsika et al., 2010) (Figure 3-2C). These oligomers run at an apparent molecular weight
of approximately 52kDa on an SDS-PAGE gel, indicating stability in the presence of
SDS and boiling (Tsika et al., 2010) (Figure 3-2C). When the brainstem and spinal cord
of a symptomatic A53T α-synuclein mouse were analyzed by native gel, the α-synuclein
that eluted at 34Å ran at the apparent molecular weight of the 50-60kDa species
previously seen on native gel. The α-synuclein that eluted at 53Å ran on the native gel at
an apparent molecular weight of 250kDa (Figure 3-2C).
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Figure 3-2: α-Synuclein runs at an apparent molecular weight of an approximate tetramer on a
native gel. A, Triton X-100 soluble mouse brain homogenate from a non-symptomatic A53T αsynuclein transgenic mouse was run on SDS-PAGE (left) or a native gel (right) and analyzed by western
blot with an antibody specific for human α-synuclein. B, Triton X-100 soluble homogenate from the
whole brain of a non-symptomatic A53T α-synuclein mouse (N.S. brain) or from the brainstem and
spinal cord of a symptomatic A53T α-synuclein mouse (Sympt BS + SC) were analyzed along with
brain tissue from a patient with dementia with Lewy bodies (DLB) or a control patient (Ctl)
homogenized with either a detergent-free lysis buffer (No Det), a 0.5% digitonin lysis buffer (Dig), or a
1% Triton X-100 lysis buffer (TrX). These samples were run on SDS-PAGE (left) or a native gel (right)
and analyzed by western blot with an antibody specific for human
α-synuclein. C, Triton X-100 soluble homogenate from the
brainstem and spinal cord of a symptomatic A53T α-synuclein
mouse was subjected to non-denaturing size exclusion
chromatography (SEC). The SEC fractions were then analyzed by
SDS-PAGE or native gel followed by western blot with an antibody
specific for human α-synuclein. The horizontal marker indicates the
apparent molecular radius in angstroms (Å) that corresponds with
the elution volume of globular protein standards analyzed by SEC,
as well as the estimated corresponding molecular weight (MW)
based on those globular protein standards, whereas the vertical
marker indicates the mobility of molecular weight protein standards.
The left-most lane corresponds to the non-fractionated sample.
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Next, brain homogenate from an A53T α-synuclein mouse or purified
recombinant human α-synuclein were treated with various denaturing conditions and then
run on a clear native gel, to determine whether the higher apparent native molecular
weight was due to intermolecular interactions that could be broken or due to slow
migration of an unfolded protein through the gel matrix. Boiling, SDS, and urea all failed
to reduce the size of α-synuclein on the native gel in either brain homogenate or purified
α-synuclein (Figure 3-3). Therefore, this data confirms that α-synuclein behaves as an
unfolded monomer in vivo similar to how it has been characterized in vitro.

Figure 3-3:
Denaturing conditions
are unable to collapse
the higher apparent
molecular weight of αsynuclein on a native
gel. A, 50ug of nonsymptomatic A53T αsynuclein mouse brain
homogenate or 1ug of
purified recombinant
human α-synuclein was
either untreated, boiled
for
10
minutes,
incubated with 1%
Triton, 1% SDS, or 8M
Urea, or treated with
1% SDS followed by
10 minutes of boiling.
The samples were then
run on a non-denaturing
clear
native
gel
followed by western
blot with a human
specific
α-synuclein
antibody
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Lipids have been shown to promote the formation of α-synuclein multimers
(Perrin et al., 2001; Sharron et al., 2003).

Additionally, CMA has been shown to

participate in cholesterol metabolism, and lipid levels can also regulate CMA activity
(Eskelinen et al., 2004; Kaushik et al., 2006; Schneede et al., 2009). Consequently,
imbalance in the homoeostatic balance of CMA activity and lipid levels may create a
double insult of decreased CMA function and increased lipids, both of which promote αsynuclein aggregation. To examine this possibility, the levels of several markers of lipid
metabolism were examined. Apolipoprotein E (ApoE) is involved in the metabolism of
triglyceride-rich lipoproteins. A role for ApoE in neurodegeneration was first suggested
following association of an allelic variant of ApoE as a genetic risk factor for
Alzheimer’s disease (Corder et al., 1993). However, the precise contribution of ApoE to
disease is unclear. ApoE knockout mice display neurodegeneration as well as memory
defecits (Masliah et al., 1995; 1997; Buttini et al., 1999). However, symptomatic A30P
α-synuclein transgenic mice have been shown to have increased levels of ApoE and
crossing these mice with ApoE knocknout mice delayed α-synuclein induced
neurodegeneration and suppressed the accumulation of Aβ (Gallardo et al., 2008). In this
study, levels of ApoE were examined in the spinal cord, a region that forms prominent
inclusions in A53T α-synuclein mice, and the hippocampus, a region with minimal
inclusions, in an A53T α-synuclein mice that had developed motor symptoms, agematched A53T α-synuclein mice that had not yet developed symptoms, age-matched nontransgenic mice, and young A53T α-synuclein mice. Levels of ApoE were greater in the
hippocampus compared to the spinal cord (Figure 3-4A). This pattern was present even
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in the non-transgenic mice and did not change with transgene expression or symptom
onset (Figure 3-4A).
The low-density lipoprotein receptor (LDLR) is involved in the delivery of
triglycerides and cholesterol to lysosomes. It binds low-density lipoproteins through
ApoB and intermediate density lipoproteins through ApoE and ApoB.

LDLR is

upregulated when the cell detects a need for free cholesterol. mRNA levels of LDLR
were increased in fibroblasts deficient in both Lamp-1 and Lamp-2 (Schneede et al.,
2009). Examination of the levels of LDLR mRNA in the hippocampus and spinal cord of
a symptomatic A53T α-synuclein mouse, an age-matched A53T α-synuclein mouse, an
age-matched non-transgenic mouse, and a young A53T α-synuclein mouse revealed an
increase in LDLR expression in the spinal cord relative to the hippocampus in all
conditions (Figure 3-4B).
Given the previously characterized regional differences in Lamp-2a expression
(Chapter 2), it was important to decipher whether differences in lipid levels facilitate
changes in the CMA pathway, specifically Lamp-2a expression. To examine the effect of
increased lipid levels on CMA, the levels of Lamp-2a were compared in the brainstem
and spinal cord of ob-/ob- mice and non-transgenic mice.

Ob-/ob- mice lack the

metabolic hormone leptin and consequently possess increased levels of triglycerides and
cholesterol. No differences in Lamp-2a expression were observed between the ob-/obmice and the nontransgenic mice (Figure 3-4C).
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Figure 3-4: Alterations in lipid
metabolism components in a
region that develops prominent αsynuclein inclusions compared to
a region that develops minimal
inclusion. A, The hippocampus
(Hipp) and the spinal cord (SC)
from symptomatic A53T α-syn
transgenic mice, age matched nonsymptomatic
A53T
α-syn
transgenic mice (non-sympt), age
matched
non-transgenic
mice
(nonTg), and young A53T α-syn
transgenic mice (2.5mo) (young)
were analyzed by SDS-PAGE /
western blot for ApoE. NSE was
used as a loading control. (n=3) B,
Quantitative PCR with a primer
against LDLR and a primer against
neuron specific enolase (NSE) as a
control was performed on cDNA
synthesized from RNA extracted
from same conditions described
above. Levels of LDLR mRNA in
the spinal cord were held relative to
the levels in the hippocampus of the
same mouse. (n=1). C, The
hippocampus (Hipp) and the
brainstem (BS) from a nontransgenic littermate of the A53T αsynuclein mice (nTg A53T -/- ) or
an ob-/ob- mouse were analyzed by
SDS-PAGE / western blot for
Lamp-2a. NSE was used as a
loading control (n=2).

3.5 Discussion
While failure of protein degradation systems has been shown to promote the
aggregation of proteins implicated in the pathogenesis of neurodegenerative diseases, this
causative interaction has been studied in model systems overexpressing the protein of
interest (Stefanis et al, 2001; Paxinou et al., 2001, Webb et al., 2003; Vogiatzi et al.,
2008). Therefore, during the development of sporadic PD, it is unclear how α-synuclein
is selectively vulnerable to proteolytic dysfunction.
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The present study investigated

potential factors that could contribute to the preferential initiation of α-synuclein
aggregation. Three possibilities were explored: impaired recognition by the degradation
system, a native state of the α-synuclein that prevented uptake, and modulation by an
outside component that selectively promoted α-synuclein aggregation.
The CMA chaperone Hsc70 was able to associate with α-synuclein, suggesting
that it can transport the substrate to the lysosome for degradation. In A53T α-synuclein
mice that have not developed motor symptoms, there was no difference in the ability of
Hsc70 to associate with α-synuclein in brain regions that develop prominent inclusions
compared to brain regions that develop minimal inclusions.

Therefore, impaired

recognition of α-synuclein by the CMA chaperone does not appear to participate in the
initiation of α-synuclein aggregation. However, in symptomatic A53T α-synuclein mice,
Hsc70 had decreased association with α-synuclein in the inclusion-forming region of the
spinal cord. Therefore, it appears that Hsc70 cannot clear already formed inclusions.
This reinforces the fact that CMA is an ineffective degradation system for α-synuclein
following the onset of disease.
Investigations next focused on determining whether α-synuclein is natively found
in soluble oligomeric complexes in vivo. Because substrates must be unfolded to pass
through the Lamp-2a receptor, such multimers could impede the ability of α-synuclein to
be properly degraded. While α-synuclein from both the transgenic mouse brain and
human brain were found to run at a higher apparent molecular weight on a native gel, this
was caused by the unfolded nature of α-synuclein. This parallels the larger globular
space occupied by monomeric α-synuclein in gel filtration elutions. Treatment with
various denaturing conditions such as boiling, SDS, and urea, were not able to collapse
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the size of this band on a native gel, indicating that it is not associated with itself or other
proteins. Therefore, α-synuclein is not vulnerable to aggregation due to formation of
soluble oligomeric complexes that prevent its ability to be unfolded and taken up into
lysosomes.
A final possibility involved exploration of an additional cellular component that
could accumulate alongside α-synuclein upon disruption of degradation and enhance αsynuclein aggregation. Lipids have been shown to promote the formation of α-synuclein
multimers and cholesterol metabolism is impaired in the absence of Lamp-2 (Perrin et al.,
2001; Sharron et al., 2003a; Eskelinen et al., 2004; Schneede et al., 2009). Therefore, the
levels several markers of lipid metabolism were explored. Expression of the ApoE
protein was decreased in the spinal cord relative to the hippocampus, while levels of
LDLR mRNA were increased in the spinal cord relative to the hippocampus. ApoE is
involved in the transport and catabolism of triglycerides while LDLR is involved in
recognizing and delivering trigylcerides and cholesterol to lysosomes. LDLR levels are
upregulated when the cell detects a need for free lipids, and thus the combination of
decreased levels of ApoE and increased levels of LDLR suggests that there are fewer
lipids in the spinal cord than in the hippocampus. This evidence suggests that there are
regional alterations in lipid metabolism. However, the contribution of these differences
to α-synuclein neurodegeneration is unclear. While lipids have been suggested to
promote α-synuclein aggregation, this data suggests that the regions that are most
vulnerable to inclusion formation have decreased levels of lipids.
Lamp-2 has been shown to play a role in cholesterol metabolism, with knockout
of Lamp-2 leading to an accumulation of cholesterol (Eskelinen et al., 2004; Schneede et
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al., 2009). Lamp-2a levels are increased in the spinal cord compared to the hippocampus,
which reflects the differences in lipid levels seen here. Interestingly, CMA activity has
conversely been found to be decreased in the spinal cord relative to the hippocampus,
suggesting that Lamp-2 mediated turnover of cholesterol is independent of CMA. In
deciphering the potential relationship between Lamp-2a and lipids, it was important to
determine what affect lipid levels have on Lamp-2a expression. No difference in Lamp2a expression was found between ob-/ob- mice that have significantly increased levels of
lipids and non-transgenic mice. Therefore, lipid levels do not appear to affect the overall
expression of the Lamp-2a receptor. However, cholesterol levels have been shown to
affect the distribution of Lamp-2a into functional complexes (Kaushik et al., 2006). A
decrease in lipids in the spinal cord would promote the exit of Lamp-2a from cholesterolrich regions of the lysosomal membrane and promote its multimerization into higher
molecular-weight complexes (Kaushik et al., 2006). The formation of these complexes is
required for the lysosomal uptake of substrates, and promotion of complex formation
would presumably increase CMA activity (Kaushik et al., 2006).

However, it has

previously been shown that the spinal cord has decreased levels of CMA activity relative
to the hippocampus (Chapter 2).
In a genome wide screen in yeast, approximately 25% of genes that were found to
enhance the toxicity of α-synuclein were involved in lipid metabolism (Willingham et al.,
2003). These results suggest that altered lipid metabolism occurs in the regions that are
most vulnerable to developing α-synuclein inclusions. However, further studies are
needed to better characterize the metabolic changes occurring and determine a causative
link to aggregation and toxicity.
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CHAPTER 4
Novel mechanisms for direct lysosomal uptake regulate
the regional degradation of α-synuclein.

By:
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4.1 Abstract
Impaired activity of protein degradation systems has been shown to promote the
aggregation of several proteins implicated in neurodegenerative disorders, including αsynuclein. However, the mechanisms underlying the vulnerability of select brain regions
to inclusion formation and neurodegeneration remain unknown.

Recently, we have

documented in mice that lysosomes in the brain regions that are most vulnerable to
developing α-synuclein inclusions have decreased ability to take up and degrade
substrates through CMA, despite increased expression of the CMA receptor Lamp-2a
(Chapter 2). Previously, the levels CMA activity have been characterized as showing
direct correlation to the levels Lamp-2a in the lysosomal membrane using rat liver
(Cuervo and Dice, 2000a,b). Here we document that the direct lysosomal uptake of αsynuclein is not entirely dependent on Lamp-2a in the brain. The possibility of an
additional protein that can serve as a lysosomal receptor is explored, with emphasis on a
96kDa protein recognized by the Lamp-2a antibody that has been shown to not be a
Lamp-2 isoform.

This 96kDa protein is a glycosylated protein that is enriched in

lysosomes, has increased stability compared to Lamp-2a, and has expression levels that
correlate to lysosomal activity. Western blot, mass spectrometry, and sequence analysis
suggests that Lamp-1 may be the 96kDa protein. Therefore, this data suggests that
Lamp-1 is a candidate for an alternate lysosomal protein that can recognize CMA
substrates and promote direct lysosomal uptake and degradation.
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4.2 Introduction
While the protein aggregation is a shared hallmark of an array of
neurodegenerative disorders, each of these diseases is characterized by the accumulation
of select proteins in distinct regions of the brain. Protein degradation pathways have
been shown to be important modulators of this inclusion formation.

However, the

precise contribution of different degradation systems to the unique pathology of each
disease remains unknown.

In synucleinopathies, which include Parkinson’s disease

(PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), the
protein α-synuclein has been identified as an integral component of the filamentous
inclusions that are formed (Spillantini et al., 1997, 1998a,b; Tu et al., 1998). While
manipulation of both proteasomal and autophagic pathways has been shown to affect the
turnover of α-synuclein, evidence suggests that α-synuclein is preferentially degraded by
chaperone mediated autophagy (CMA) (Stefanis et al, 2001; Paxinou et al., 2001, Webb
et al., 2003; Cuervo et al., 2004).
In CMA, cytosolic proteins containing a pentapeptide targeting motif are
selectively targeted to the lysosomal receptor lysosome-associated membrane protein
type 2A (Lamp-2a) with the aid of chaperone proteins (Cuervo and Dice, 1996). The
Lamp-2a receptor modulates the uptake of these substrates into the lysosome for
degradation. In the rat liver, levels of Lamp-2a in the lysosomal membrane show direct
correlation to the levels of CMA activity (Cuervo and Dice, 2000a,b). Mutation of the
CMA pentapeptide targeting motif of α-synuclein inhibits the direct lysosomal uptake
and degradation of the protein into isolated liver lysosomes and increases the half life and
toxicity of α-synuclein in cultured cells (Cuervo et al., 2004; Vogiatzi et al., 2010;
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Xilouri et al., 2009). In vivo, cell stress conditions that increase Lamp-2a expression
result in increased intralysosomal content of α-synuclein in mouse midbrain neurons
(Mak et al., 2010).
This evidence supports the role of α-synuclein as a CMA substrate. However,
recent evidence suggests that in the mouse brain, there are deficiencies in the ability of αsynuclein to be effectively degraded by CMA (Chapter 2). In lysosomes extracted from
the brain, levels of Lamp-2a in the lysosomal membrane do not correlate with the ability
of lysosomes to bind substrates (Chapter 2). Independent of the defect in substrate
binding, lysosomes from the regions that are most vulnerable to inclusion formation
additionally show decreased uptake and degradation of CMA substrates compared to the
regions that form minimal inclusions despite having higher levels of Lamp-2a (Chapter
2). This malfunction in substrate clearance likely contributes to the selective aggregation
of α-synuclein in these regions. However, it is unclear why lysosomes in the brain differ
in kinetics from previously characterized liver lysosomes, and additionally, what causes
this region specific deficiency in lysosomal uptake.
Lamp-2a was first characterized as the CMA receptor by sequencing a 96kDa
protein from lysosomal membrane homogenate that associated with GAPDH (Cuervo et
al., 1996). While knockdown and overexpression studies have clearly demonstrated a
correlation between receptor levels and substrate degradation, this data does not preclude
the possibility of an additional lysosomal protein that participates in the direct uptake of
substrates into lysosomes. Here we present data that suggests that an alternate route of
direct lysosomal uptake is present in brain lysosomes. Analysis of immunoreactive bands
detected by the Lamp-2a antibody suggests that a 96kDa band that is not a Lamp-2
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isoform but does represent a glycosylated lysosomal protein is a candidate for serving as
an additional lysosomal receptor. This protein has increased stability compared to Lamp2a in the lysosomes in the brain and enhanced expression in the regions that develop
fewer inclusions. Data suggests that this protein is Lamp-1 and that it may be able to
recognize CMA substrates with and consequently contribute to direct lysosomal uptake
and degradation.

4.3 Materials and Methods
Mouse breeding. The mice used in this study express human A53T α-syn (line M83)
driven by the murine PrP promoter (Jackson Laboratory, Bar Harbor, Maine) and have
been described previously (Giasson et al., 2002).

To generate the A53T+/+ and

nontransgenic (nonTg) mice used in experiments, heterozygous A53T+/- females were
mated with A53T+/- males. Genotyping was performed by both end-point PCR using
GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, Carlsbad, CA) and
quantitative PCR using Applied Biosystems 7500 real-time PCR System with the ABI
MGB primer-probe set for human SNCA, the gene that encodes α-syn (Applied
Biosystems assay ID Hs00240907_m1). SNCA values were normalized to mouse β-actin
(Applied Biosystems assay ID 4352341E).
Mouse organ dissection for biochemical analysis. For analysis of brain regions, mice
were anaesthetized with CO2 followed by cervical dislocation. The brain and spinal cord
were dissected and rinsed thoroughly with ice-cold phosphate buffered saline (PBS).
After dissection of the cerebellum, olfactory bulbs, and brainstem, the remainder of the
brain was submerged in ice-cold PBS and sliced into 1 mm thick coronal sections using a
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vibratome (World Precision Instruments, Sarasota, FL).

The brain regions of the

hippocampus, cortex, striatum, and substantia nigra were dissected away from these
sections.

For generalized brain region analysis, the brainstem and the spinal cord

“Pathogenic regions” were dissected away from the remainder of the brain “Nonpathogenic regions”, and rinsed thoroughly in cold PBS. Dissected brain regions were
weighed, rapidly frozen on dry ice, and stored at -80°C until analysis
Isolated Neural Cell Types. Astrocytes were cultured as described previously (Greco et
al., 2010).

Primary cortical and primary hippocampal neurons were gifts from Dr.

Virginia Lee (University of Pennsylvania, Philadelphia, PA).

Primary spinal cord

neurons and purified motor neurons were gifts from Dr. Serge Przedborski (Columbia
University, New York, NY). Precursor and mature oligodendrocytes were gifts from Dr.
Judith Grinspan (Children’s Hospital of Philadelphia, Philadelphia, PA).
Western Blotting. Tissue was homogenized with 10 volumes of lysis buffer [50mM Tris
(pH7.5), 150mM NaCl, 5mM EDTA, 10% Glycerol, 1% TritonX-100, 0.5% Sodium
Deoxycholate, 2% Sodium Dodecyl Sulfate, 8M Urea, 1mM PMSF, 1:50 Protease
Inhibitor Cocktail (Sigma P8340)]. Similar results were seen with the use of an alternate
lysis buffer [20mM HEPES (pH7.4), 150mM NaCl, 10% Glycerol, 1% TritonX-100,
1mM EGTA, 1.5mM MgCl2, 1mM PMSF, 1:50 Protease Inhibitor Cocktail (Sigma
P8340)]. The tissues were homogenized with the aid of a mechanical homogenizer
(Fisher Jumbo Stirrer 14-501) and then subjected to four consecutive freeze and thaw
cycles of 2 min each (-80°C ethanol bath / 37°C water bath). The sample was then
centrifuged for 30 min at 18,000xg at 4°C. The supernatant was retained and protein
concentration was determined by the microBCA assay (Thermo Fisher Scientific,
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Rockford, IL). Unless otherwise indicated, 30 μg of material was loaded per lane for
analysis by SDS-PAGE/western blot.

The tissue was analyzed with the following

primary antibodies : 1:300 Lamp-2a (Invitrogen 51-2200), 1:4000 NSE (Polysciences
Inc. 16625), 1:1000 α-syn specific for human α-syn (Syn211, Sigma S5566), 1:750
Cathepsin D (Abcam Ab6313), 1:500 Lamp-1 (Abcam Ab25630). Primary antibodies
were detected with one of the following conjugated secondary antibodies: goat anti-rabbit
IgG IRDye680 (1:5000, Rockland), donkey anti-mouse IgG IRDye800 (1:5000,
Rockland), donkey anti-mouse IgG IRDye680 (1:5000, Rockland) and scanned with the
Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE). The protein bands
from the western blots were quantified by densitometry using Odyssey infrared imaging
system software (Odyssey version 2.1, Li-Cor Biosciences, Lincoln, NE).
Deglycosylation assay. Fifty micrograms of homogenate from the hippocampus and
spinal cord of non-transgenic mice was denatured for 5 min at 100°C, briefly cooled, and
then incubated at 37°C with a cocktail of enzymes that perform N- and O- linked
deglycosylation; PNGaseF; α-2(3,6,8,9) Neuraminidase; O-Glycosidase; β (1-4)
Galactosidase; β-N-Acetylglucosaminidase; Endoglycosidase H (3.33 µl each; Sigma EDEGLY Kit, and Sigma A0810) for varying times. After incubation, the enzymes were
heat inactivated, and the samples were analyzed by SDS-PAGE/western blot.
Lysosome Extraction. Brain tissue was homogenized in Tris-buffered 0.25M Sucrose
(pH 7.4) with 1:50 Protease Inhibitor Cocktail (SigmaP8340) and centrifuged at 6,800xg
15 min at 4°C. After washing the pellet with sucrose, the combined supernatants were
centrifuged at 21,000xg 30 min at 4°C. The supernatant was retained as the “cytoplasmic
fraction” and the pellet, which contained the light mitochondria and lysosomes (light
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M+L fraction), was re-suspended in 0.25 M Sucrose.

The mitochondria were then

precipitated out of the M+L fraction by incubation with 115 µM CaCl2 for 30 min. The
sample was then centrifuged 5,000xg for 10 min at 4°C to pellet the mitochondria. The
supernatant, which contains the lysosomes, was collected and centrifuged again at
5,000xg for 10 min at 4°C to ensure purity. The supernatant was retained and centrifuged
at 21,000xg for 30 min at 4°C to pellet the lysosomes. The lysosomes were then resuspended in 300 µl reaction buffer (10 mM MOPS, pH 7.3, 0.25 M Sucrose, 5.4 µM
cysteine, 1 mM DTT). Protein concentration was measured by a micro-BCA protein
assay, and lysosomal integrity was verified by an assay measuring the activity of the
lysosomal

enzyme

β-Hexosaminidase

with

the

flourogenic

substrate

4-

methylumbelliferyl-N-acetyl-β-glucosaminide dehydrate (Sigma M2133) in a fraction of
lysosomes compared to the non-sediment medium. The enrichment of lysosomes and
absence of mitochondria from this lysosomal fraction was verified by western blot with
antibodies against Lamp-2a (Abcam ab18528) and Cytochrome c oxidase subunit 1
(MTCO1) (Abcam ab14705).
Lysosomal Activity Assays. Human recombinant α-syn protein used for the assay was
expressed and purified as described previously (Giasson et al., 1999). Twenty five
micrograms of lysosomes purified as described above were incubated for 30 min at 37°C
with 0.2 µg of purified human α-syn, 10 µl of “6x Energy Regenerating System” (60 mM
MgCl2, 60 mM ATP (Sigma A2383), 12 mM Phosphocreatine, 30 µg creatine
phosphokinase, in 0.25 M Sucrose, pH 7.4), 0.6 µg Hsc70 (Enzo Life Science,
Farmingdale, NY), and brought up to 60 µl with reaction buffer (10 mM MOPS, pH 7.3,
0.25 M Sucrose, 5.4 µM Cysteine, 1 mM DTT). One set of samples additionally had a
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40M excess of GAPDH (24.5ug) (Sigma G5262) or ovalbumin (19.8ug) (Sigma A5503)
added to the incubation.

Control conditions were run in parallel with either no

lysosomes, in which proteolysis buffer was substituted for the lysosomes, or with burst
lysosomes. For the burst lysosomes, 25 µg of lysosomes were centrifuged at 21,000xg
for 8 min at 4°C. The supernatant was discarded and the pelleted lysosomes were
subjected to hypotonic shock by re-suspension in 0.025 M Sucrose (pH 7.4) for 30 min
on ice followed by two cycles of freeze/thaw. These burst lysosomes were then added to
the assay in place of the intact lysosomes. For the burst lysosomes, the neutral reaction
buffer used for the intact lysosomes was replaced with an acidic reaction buffer (10 mM
citrate buffer, pH 5.0, 0.25 M Sucrose, 5.4 µM cysteine, 1 mM DTT). At the end of the
assay, the reaction was stopped by adding a protease inhibitors including 1:30 Protease
Inhibitor Cocktail (SigmaP8340) and 1 mM PMSF.

Samples were subjected to

SDS/PAGE alongside standards of purified human α-syn followed by western blot with a
human specific α-syn antibody (Syn211, Sigma S5566).
Endogenous Degradation Asssays
Seventy five micrograms of lysosomes purified as described above were incubated at
37°C with 5 µl of “6x Energy Regenerating System” (60 mM MgCl2, 60 mM ATP
(Sigma A2383), 12 mM Phosphocreatine, 30 µg creatine phosphokinase, in 0.25 M
Sucrose, pH 7.4), and brought up to 30 µl with reaction buffer (10 mM MOPS, pH 7.3,
0.25 M Sucrose, 5.4 µM Cysteine, 1 mM DTT). At the end of the assay, the reaction was
stopped by adding a protease inhibitors including 1:30 Protease Inhibitor Cocktail
(SigmaP8340) and 1 mM PMSF. Samples were subjected to SDS/PAGE followed by
western blot with an antibody against Lamp-2a (Abcam18528).
99

In gel digestion and MS/MS analysis. Duplicate samples of 50ug of lysosomes and
lysosomal membranes purified as described above were mixed with 6X Laemmli sample
buffer and separated on a 10% Bis-tris Novex Nupage gel (Invitrogen NP0301). One set
of the lysosomes and lysosomal membranes was analyzed by western blot for Lamp-2a as
described above. For the other set of lysosomes and lysosomal membranes, the gel was
visualized by colloidal blue stain (Invitrogen LC6025). Stained gels were processed by
in-gel trypsin digestion according to the following protocol. Slices were cut from the gel
at apparent molecular weights corresponding to the Lamp-2a bands in the parallel
western blot. Each slice was placed in single well of an Axygen plate and destained with
110ul of destain buffer (50% methanol, 1% acetic acid, 49% water) overnight at room
temperature on a rotator. Destained gel pieces were dehydrated in 100ul of acetonitrile
(ACN) for 5min at room temperature. Acetonitrile was aspirated off and 5 mM Tris(2carboxyethyl)phosphine hydrochloride (TCEP) in 50mM ammonium bicarbonate buffer
was added for 15 minutes at 370C in order to reduce cysteine thiols. Subsequently,
cysteine thiols were alkylated with 50 mM iodoacetamide in 25mM ammonium
bicarbonate buffer for 30 minutes at 370C in the dark. Iodoacetimide treatment results in
additional mass of 57 amu to the cysteine thiol and the carboxyamidomethylated cysteine
is used as a static modification when the experimental data is searched against theoretical
databases. In the next step the gel pieces were dehydrated with 100ul acetonitrile and
hydrated with 100ul of 10mM AmBic for 5 minutes at room temperature. Next, 100ul of
acetonitrile were added for 5 minutes followed by 50ul of 10mM AmBic containing
10ng/ul of trypsin. Trypsin digestion was performed for six hours at 370C. Tryptic
peptides were extracted from the gel with 50ul of 0.3% formic acid for 2 hours at room
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temperature on a rotator. Supernatants (about 100ul) were transferred to Axygen tubes
and gel pieces were incubated with 50% ACN for additional two hours at room
temperature. Liquid was recovered and combined with formic acid extracts. The volume
was reduced to 5ul with speedvacing and adjusted to the desired volume (about 15ul)
with 0.1% formic acid. Tryptic peptide digests were analyzed by hybrid LTQ-Orbitrap
mass spectrometer (Thermo Electron, San Jose, CA) coupled to an Eksigent 2D LC
system (Eksigent Technologies, Livermore, CA) and autosampler. Buffers A and B were
0.1 % formic acid/1 % methanol and 80% acetonitrile/0.1 % formic acid/1 % methanol,
respectively. Peptides were loaded isocratically onto a C18 trap column (75 um i.d. x 25
mm; New Objective Proteopep 2) at a flow rate of 1 μl per minute in 2% B. Peptides
were then eluted onto a C18 analytical column (75 um i.d. x 150 mm; New Objective
Proteopep 2). A linear gradient was then initiated at a flow rate of 300 nL per minute for
90 min from 3 - 40% B. The mass spectrometer was set to repetitively scan from 375 to
1600 m/z followed by data-dependent MS/MS scans on the five most abundant ions with
dynamic exclusion enabled.
Generation and evaluation of SEQUEST peptide assignments. DTA files were generated
from MS/MS spectra extracted from the RAW data file (intensity threshold of 2500;
minimum ion count of 50) and processed by the ZSA and Correction algorithms of the
SEQUEST Browser program. DTA files were submitted to Sorcerer-SEQUEST (ver.
4.0.3, rev 11; Sagen Research, San Jose, CA) using the following parameters: Database
searching was performed against a Uniprot database (Release v3.57; 3/24/2009)
containing Mus musculus sequences from Swiss-Prot plus common contaminants, which
were then reversed and appended to the forward sequences. The database was indexed
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with the following parameters: mass range of 600 – 3500, tryptic cleavages with a
maximum

of

2

missed

cleavage

and

static

modifications

of

cysteine

by

carboxyamidomethylation (+57 amu). The DTA files were searched with a 50 ppm
peptide mass tolerance for LTQ-Orbitrap, 1.0 amu fragment ion mass tolerance, and
variable modification of methionine (+16 amu) for in-gel digestion, and maximum
number of variable modifications of 3. Potential sequence-to-spectrum peptide
assignments generated by Sorcerer-SEQUEST were loaded into Scaffold (version 2.2;
Proteome Software, Portland, OR) to validate protein identifications.

Protein

identifications were accepted at a threshold of ≥ 99 % protein confidence with ≥ 2 unique
peptides at ≥ 80 % confidence. These criteria resulted in an estimated protein false
discovery rate (FDR) of ≤ 5 %, as calculated by the number of hits to the reverse protein
sequences.
Statistical Analysis. Data were analyzed using the Graphpad Prism Software (version
5.02) and were expressed as the mean ±SEM. A t-test was used to determine whether
two conditions were significantly different. p values <0.05 were considered statistically
significant.

4.4 Results
In the mouse brain, levels of Lamp-2a are greatest in the regions of the brainstem
and spinal cord, which are the two regions that develop the most prominent inclusions
upon expression of human A53T α-synuclein (Chapter 2). Functionally, the increased
expression of Lamp-2a in the mouse brain does not lead to CMA upregulation as
previously characterized for rat liver lysosomes. In fact, the lysosomes of brainstem and
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spinal cord incongruously have decreased ability to take up and degrade substrates
compared to other brain regions (Chapter 2). To dissect the cause of this discrepancy, a
lysosomal activity assay for α-synuclein degradation was performed in the presence of a
competing CMA substrate.

Previous studies have shown that Lamp-2a mediated

degradation of one CMA substrate is inhibited by the presence of another CMA substrate
in excess (Cuervo et al., 1994; 1996; 2004).

Therefore, purified lysosomes were

extracted from the brainstem and spinal cord or from the remaining brain regions and
then incubated with a mixture that included an energy-regenerating system containing
ATP, the Hsc70 chaperone, and exogenous human α-syn. In addition to α-synuclein, one
condition of lysosomes from each of these regions was also incubated with a 40 Molar
excess of GAPDH, an established CMA substrate, or ovalbumin, a protein known to not
be degraded through CMA. As an additional control, a condition of burst lysosomes was
included to account for differences in protease activity across the two regions. The
amount of α-syn remaining was then determined by quantitative western blot with an
antibody specific to human α-syn.

As previously established, lysosomes from the

pathogenic regions have decreased ability to take up and degrade α-synuclein compared
to non-pathogenic regions. However, the addition of neither GAPDH nor ovalbumin
affected the uptake and degradation of α-synuclein (Figure 4-1). It has previously been
shown that this uptake and degradation requires ATP and is inhibited at low temperature
that prevent lysosomal uptake (Chapter 2). Additionally, macroautophagy cannot play a
role as autophagosome formation is not able to occur in this isolated system. Therefore,
it appears that in the brain α-synuclein is directly taken up and degraded by lysosomes
but is not competed by other CMA substrates in the manner characterized for Lamp-2a
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mediated uptake. Therefore, a factor other than Lamp-2a may be contributing to this
discrepancy in rates of α-synuclein uptake and degradation across brain regions.

Figure 4-1. Direct lysosomal uptake and degradation of α-synuclein is not sensitive to
competition by the CMA substrate GAPDH.
Purified lysosomes were extracted from the
pathogenic regions of the brainstem and spinal cord (“Path”) or the remainder of the brain (“NonPath”) of non-transgenic mice. 25µg of purified lysosomes were incubated with 0.2 µg of purified
human α-syn with Hsc70 and an energy regenerating system at 37°C. Where indicated, a 40M
excess of GAPDH or ovalbumin were added to the incubation. After the incubation, the samples
were analyzed by SDS-PAGE/western blot with a human specific α-syn antibody and quantified by
densitometry. 25µg of lysosomes burst by hypotonic shock were also incubated with 0.2µg of α-syn
under the same conditions as a control for the activity of lysosomal proteases in the two samples. All
values were held relative to a final condition in which the 0.2 µg of α-syn was incubated under the
same conditions only without any lysosomes present. GAPDH failed to decreased the lysosomal
uptake and degradation of α-synuclein (n=3) (*p<0.05 path versus non-path regions, t-test).

While Lamp-2a has previously been characterized as a 96kDa protein in rat liver
(Cuervo et al., 1996), in the mouse brain Lamp-2a is differentially glycosylated and
expressed as a protein with an apparent molecular weight of 72kDa (Chapter 2).
However, western blots developed with two different antibodies against Lamp-2a also
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recognize a 96kDa band (Chapter 2). This band is not a Lamp-2 isoform as it is present
in Lamp-2 knockout mice (Chapter 2). Antibodies that specifically recognize Lamp-2a
are designed against the twelve amino-acid C-terminal tail of the protein, as this is the
only region that differs among the alternatively spliced Lamp-2a, Lamp-2b, and Lamp-2c
isoforms (Cuervo et al., 1996). This is also the region of Lamp-2a that extends from the
lysosome into the cytoplasm and recognizes and binds CMA substrates. Therefore, the
possibility exists that if Lamp-2a antibodies recognize the particular epitope of a protein
as homologous to the C-terminus of Lamp-2a, CMA substrates may similarly have an
affinity for binding to this epiotpe. This 96kDa band was found to be enriched in purified
lysosomes (Figure 4-2A).

Additionally, the pattern of expression of this band correlates

with the levels of lysosomal uptake and degradation, with the lowest levels of expression
in the brainstem and spinal cord and increased expression in the remainder of the brain
regions (Figure 4-2B). Examination of different neural cell types revealed that this band
is preferentially found in neurons but not glia (Figure 4-2C). Similar to Lamp-2a, this
96kDa species was able to be deglycosylated. However, while Lamp-2a was readily
deglycosylated within 10 minutes, the 96kDa protein was able to be recognized at 24
hours (Figure 4-2D). Following deglycosylation, the backbone of the 96kDa collapsed to
an apparent molecular weight of approximately 45kDa. Examination of the lysosomal
stability of this protein was also performed. Purified lysosomes were incubated with an
energy regenerating system containing ATP at 37°C for various timepoints.

The

lysosomes were then analyzed by western blot with the Lamp-2a antibody that recognizes
both Lamp-2a and the 96kDa band. While it was difficult to determine whether the
persistence of the 96kDa band was merely due to increased immunoreactivity or to a
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longer half-life, this protein was detectible in lysosomes for a longer period of time than
Lamp-2a (Figure 4-2E).
Figure 4-2. A 96kDa
band detected by
Lamp-2a antibodies
is a glycosylated
lysosomal
protein
that is more stable
than Lamp-2a. A,
Extracted lysosomes
from the cortex or
brainstem were run
alongside a nonfractionated
homogenate (whole
cell) and analyzed by
SDS-PAGE/western
blot for Lamp-2a.
The 96kDa band is
enriched in lysosomal
fractions. Cathepsin
D was used as a
marker for lysosome
enrichment. (Ctx –
cortex;
BS
–
brainstem). B, The
brains
of
nontransgenic mice were
dissected into eight
specific regions and
analyzed by SDSPAGE/western blot
for Lamp-2a. NSE served as a loading control. (SN - substantia nigra; OlfB - olfactory bulbs; Str striatum; Hipp - hippocampus; Ctx - cortex; Crb - cerebellum; BS - brainstem; SC - spinal cord). The
96kDa band has the lowest levels of expression in the brainstem and spinal cord. C, Examination of
different purified neural cell types by SDS-PAGE/western blot for Lamp-2a indicates that the 96kDa
band is found in a variety of neuronal cell types but is not found in astrocytes or oliogdendrocytes.
The amount of protein loaded for each cell type was adjusted to yield signals of relatively consistent
intensity (Cortex, 30 µg; Hippocampus, 20 µg; Spinal Cord, 15 µg; Motor Neurons, 50 µg;
Astrocytes, 1.5 µg; Precursor Oligodendrocytes, 1.5 µg; Mature Oligodendrocytes, 1.5 µg). D, The
96kDa immunoreactive band is able to be deglycosylated, though less readily than the 72kDa L2A.
The hippocampus (Hipp) and spinal cord (SC) of an non-transgenic mouse were incubated PNGaseF;
α-2(3,6,8,9) Neuraminidase; O-Glycosidase; β(1-4) Galactosidase; β-N-Acetylglucosaminidase;
Endoglycosidase H).
After incubation, the enzymes were heat inactivated, and the samples were
analyzed by SDS-PAGE/western blot for Lamp-2a. E, To determine the endogenous turnover of the
96kDa immunoreactive band and the 72kDa Lamp-2a, 75ug purified lysosomes were incubated for the
indicated timepoints at 37°C with an energy regenerating system containing ATP. After the
incubation, the samples were analyzed by SDS-PAGE/western blot with a Lamp-2a antibody and
quantified by densitometry. All values were held relative to a condition in which the lysosomes were
immediately frozen. Detectable levels of imunoreactivity persisted for a longer period of time for the
96kDa band.
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The finding that this 96kDa protein is enriched in lysosomes and is heavily
glycosylated suggested that this protein may also be a lysosomal membrane protein.
Lamp-2a is a member of a family of heavily glycosylated transmembrane proteins that
includes lysosome associated membrane protein-1 (Lamp-1).

Lamp-1 and Lamp-2

possess a 37% sequence homology and are structurally very similar: the region of each
protein that is located within the lysosomal lumen is heavily decorated with N-linked
glycans and four disulfide bonds and is composed of two homologous domains linked by
a hinge region enriched in proline, serine, and threonine and modified by several Olinked glycans.

Mouse Lamp-1 has a backbone of 43,865 daltons, which is the

approximate molecular weight of the deglycosylated form of the 96kDa protein. Lamp-1
and Lamp-2 are believed to have overlapping functions, as mice deficient in one of the
two proteins are viable, but double knockout mice are embryonic lethal (Andrejewski et
al., 1999; Tanaka et al., 2000; Eskelinen et al., 2004).

Furthermore, Lamp-2 is

upregulated in mice lacking Lamp-1 (Andrejewski et al., 1999). Western blot for Lamp-1
revealed a band of approximately 96kDa (Figure 4-3A).

Mass spectrometry was

performed on a 96kDa region extracted from a lane of an SDS-PAGE gel in which a
lysosome enriched fraction was separated. Four peptides corresponding to Lamp-1 were
identified (Figure 4-3B). The twelve amino acid cytosolic C-terminus of Lamp-2a is
responsible for substrate binding. Lamp-1 has a 50% homology to Lamp-2a, when
sequences are compared between both the mouse and human proteins (Figure 4-3C).
However, the majority of these amino acid substitutions involve amino acids with similar
biochemical properties, such as lysine and arginine which both have basic side chains or
phenylalanine and isoleucine which have both bulky hydrophobic side chains. Within
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this C-terminal region, a series of four positively charged amino acids within Lamp-2a
are critical for substrate binding

406KRHH409

(Cuervo and Dice, 2000b). In Lamp-1,

three of these four amino acids are conserved 397KRSH400 (Figure 4-3C).

Figure 4-3. Lamp-1 is a candidate for the 96kDa lysosomal protein and alternate lysosomal
receptor. A, Analysis of tissue from the brainstem and spinal cord (“Path”) or the remainder of the
brain (“Non-Path”) by SDS-PAGE/Western Blot for Lamp-1 revealed a band with an apparent molecular
weight of approximately 96kDa. B, A region corresponding to 96kDa of a lysosomal extraction run on
an SDS-PAGE gel was excised, digested with trypsin, and analyzed by Mass spectrometry. Four
peptides corresponding to Lamp-1 were identified. C, Alignment of the sequences of the twelve
cytoplasmic C-terminal residues of Lamp-2a and Lamp-1 from the mouse and human.

4.5 Discussion
The ability of Lamp-2a to dynamically control the direct lysosomal uptake and
degradation of substrate proteins has been well documented (Cuervo and Dice, 1996;
Cuervo and Dice, 2000a, 2000b). However, studies characterizing the expression of this
protein have utilized an antibody generated against the twelve amino acids of the Cterminal tail of Lamp-2a. (Cuervo et al., 1996; Cuervo and Dice, 2000a,b; Kiffin et al,
2004; Bandyopadhyay et al., 2008, Mak et al., 2010). Using Lamp-2 knockout mice we
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have recently demonstrated that this antibody recognizes species other than Lamp-2a
(Chapter 2).

Therefore, the specificity of some documented changes in Lamp-2a

expression are potentially controversial.
Within the mouse brain, levels of Lamp-2a expression are highest in the
brainstem and the spinal cord, but direct lysosomal uptake and degradation is decreased
in those areas compared with the remainder of the brain (Chapter 2). Therefore, the
possibility that an alternate mechanism may be contributing to the direct lysosomal
uptake of proteins was explored. To further explore the kinetics of lysosomal uptake and
degradation, the degradation of α-synuclein by extracted lysosomes was examined in the
presence of an excess of GAPDH, a known CMA substrate.

GAPDH failed to

competitively decrease the degradation of α-synuclein. This suggests that the uptake of
substrates through the lysosomal receptor are not saturated by the application of
exogenous substrates. Combined with the evidence that the levels of substrate uptake and
degradation are not proportional to the levels of the Lamp-2a receptor (Chapter 2), this
suggests that direct lysosomal uptake of substrates is occurring independent of Lamp-2a.
Substrate binding in CMA is mediated through the twelve amino acid c-terminal
region of Lamp-2a. This is the same region that the Lamp-2a antibody is generated
against.

Therefore, the nonspecific 96kDa band that is identified by the Lamp-2a

antibody was a candidate for an alternate protein that can mediate the binding and uptake
of substrates into lysosomes. This 96kDa band was enriched in lysosomes and able to be
deglycosylated, supporting the validity of this band as a protein of interest. Additionally,
the stability of this protein in isolated lysosomes or when exposed to degylcosylating
enzymes was greater than that of Lamp-2a in the brain. In mouse brain, Lamp-2a has an
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apparent molecular weight of 72kDa. This is smaller than its previously characterized
96kDa size identified in the rat liver and is attributable to decreased glycosylation
(Chapter 2). Due to the lysosomal localization of Lamp-2a, the prolific glycans that
decorate this protein serve a critical role in protecting Lamp-2a from degradation by
lysosomal proteases. Removal of the N-linked glycans has been shown to result in rapid
degradation of Lamp-2 (Barriocanal et al., 1986; Kundra et al., 1999). Therefore, it is
possible that the Lamp-2a that is found in the mouse brain has decreased stability
compared to the liver. While Lamp-2a may serve as a functional receptor for the uptake
and degradation of substrates in the liver, the decreased stability of the protein may
minimize the role it plays in the uptake and degradation of substrates in the lysosomes of
the brain. As compensation, additional lysosomal proteins may be able to recognize
substrates and facilitate their lysosomal uptake. This data suggests that the 96kDa protein
can act as a stable lysosomal protein in the brain.
Examination of the immunoreactive pattern of the

glycosylated and

deglycosylated 96kDa protein as well as sequence homology suggested Lamp-1 as a
candidate for the 96kDa band. This was supported by mass spectrometry that identified
Lamp-1 peptides in the 96kDa region of lysosomal fractions. The homology between the
four amino acid
and the

406KRHH409

397KRSH400

sequence that is criticial for binding substrates to Lamp-2a

residues of Lamp-1 indicate that Lamp-1 may be able to bind

substrates at the lysosomal membrane. Levels of Lamp-1 have previously been shown to
not correlate with CMA activity (Cuervo and Dice, 2000b).

However, this study

examined liver lysosomes isolated from rats starved for different periods of time, a
process that induces increased levels of Lamp-2a in the lysosomal membrane due to
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recruitment of reserve protein from the lysosomal lumen (Cuervo and Dice, 2000b).
Additionally, no change in the intensity of the 96kDa band of Lamp-2a antibody
immunoreactivity occurred with symptom onset in the A53T α-synuclein mice.
However, while Lamp-2a may act as the dynamic regulator of CMA activity during times
of cellular flux this does not preclude Lamp-1 from playing an additional static role in the
uptake and degradation of lysosomal substrates.
In summary, this data supports the fact that that within the mouse, brain direct
lysosomal uptake and degradation of substrates is occurring independent of Lamp-2a.
This evidence suggests that Lamp-1 is a candidate alternate receptor for direct lysosomal
uptake of substrates. Lamp-2a serves as a dynamic regulator of CMA activity during
times of cellular stress. However, in areas such as the brain where Lamp-2a may have
decreased stability and be less able to functionally bind and take up substrates, alternate
proteins such as Lamp-1 may be able to participate in the recognition of substrates for
direct lysosomal uptake.

111

CHAPTER 5
Summary and Discussion
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Dysfunction of protein homeostasis has been proposed to play a key role in the
protein aggregation and cell death that characterizes neurodegenerative disorders.
However, it is unclear why pathology develops preferentially in certain brain regions and
involves select proteins. Understating the basis of these vulnerabilities will provide great
insight into the underlying mechanisms causing disease. Therefore, the present thesis
aimed at investigating the regionally selective differences in lysosomal function and αsynuclein homeostasis that contribute to aggregation in the brain. Investigations utilized
a mouse model of synucleinopathy and specifically focused on CMA, a pathway shown
to degrade α-synuclein in vitro and in vivo (Cuervo et al., 2004; Vogiatzi et al., 2008;
Mak et al., 2010).

5.1 Decreased lysosomal activity provides a mechanism for regional α-synuclein
aggregation.
In Chapter 2, we documented the novel finding that the brainstem and spinal cord,
the regions that develop the most extensive inclusions in A53T α-synuclein transgenic
mice, have decreased levels of CMA activity compared to regions that develop minimal
inclusions.

This deficiency is inherent to the different brain regions and was not

dependent on transgene expression. Additionally, decreased levels of Cathepsin D and
LC3II/I in the spinal cord compared to the hippocampus suggest that decreased numbers
of lysosomes and autophagosomes are present in the regions prone to developing
inclusions. Recently, Dehay et al. (2010) documented decreased numbers of lysosomes
in the dopaminergic neurons of a 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine mouse
model of PD and in PD brain samples.

However, the decrease in lysosomes, as
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documented

by

Lamp-1

immunoreactivity

was

accompanied

by

impaired

autophagosome-lysosome fusion, which led to increased LC3II/I levels (Dehay et al.,
2010).
While PD in humans is most directly associated with pathology in the substantia
nigra pars compacta, it has been proposed that Lewy body inclusions originate in the
brainstem and anterior olfactory areas (Braak et al., 2006). Therefore, impaired CMA in
the brainstem and spinal cord provides a potential mechanism for the regionally selective
α-synuclein aggregation in disease.

The function of CMA in these regions is of

additional interest given the long axons of these neurons. The population of lysosomes
that is most active for CMA is preferentially localized to the perinuclear region of the cell
(Cuervo and Dice, 2000b).

α-Synuclein, on the other hand, is concentrated in the

presynaptic terminals (Jakes et al., 1994; Maroteaux et al., 1988; Iwai et al., 1995).
Therefore, effective transport of α-synuclein to the lysosomes for CMA may be more
challenging in neurons with long axons. In support of this, α-synuclein aggregates have
been prominently detected in neurites of patients with PD (Duda et al., 2002) and in the
synaptic terminals of patients with DLB (Kramer and Schulz-Schaeffer, 2007). Axonal
degeneration has also been described for the mice expressing human A53T α-synuclein
(Giasson et al., 2002).
Presently, no pharmacological agents have been described to selectively upreglate
CMA activity. However, development of such compounds would provide a potential
therapeutic tool for PD.

While CMA cannot clear already formed aggregates,

upregulation of CMA could serve as an early-stage preventative therapy and be used in
conjuction with upregulators of macroautophagy.
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5.2 Lamp-2a levels do not correlate with the levels of CMA substrate binding or
uptake in the brain.
Previous studies have documented that in the presence of cellular stressors, CMA
activity is upregulated through increased levels of Lamp-2a at the lysosomal membrane.
This occurs either through increased gene transcription, such as during oxidative stress,
or through recruitment of already transcribed Lamp-2a proteins, as occurs during
starvation (Cuervo and Dice, 2000b; Kiffin et al., 2004; Mak et al., 2010). In chapter 2,
Lamp-2a mRNA and protein levels were shown to be dramatically increased upon the
onset of motor symptoms in A53T α-synuclein mice. This timepoint corresponds to the
development of α-synuclein aggregates in these mice and the upregulation occurred
selectively in the regions that develop the most prominent inclusions. Therefore, it
appears that CMA is able to dynamically respond to alterations in α-synuclein
homeostasis through regulation of Lamp-2a levels. However, this increase in Lamp-2a
expression does not lead to an increased ability of lysosomes to bind CMA substrates.
Measurement of the direct lysosomal uptake and degradation of exogenously added or
endogenously associated substrates further revealed that CMA activity across regions is
not proportional to the levels of Lamp-2a in the mouse brain. Interestingly, within the
regions that develop prominent inclusions, CMA activity did increase proportionally to
Lamp-2a upregulation. Therefore, it appears that within the brainstem and spinal cord,
CMA activity is regulated by Lamp-2a expression.

However, across various brain

regions, a Lamp-2a independent factor contributes to regional differences in CMA
degradation. This differs from previous characterizations of the relationship between
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Lamp-2a levels and CMA activity that have shown a direct correlation (Cuervo and Dice
2000a, 2000b). Therefore, it appears that the regulation of CMA in the brain differs from
CMA previously characterized in the liver.
To fully understand the relevance of these findings for human disease,
preliminary data examined Lamp-2a expression in the inclusion-forming region of the
cingulate cortex from a patient with PD, a patient with DLB, and a control patient.
Lamp-2a mRNA was increased in the disease conditions, with a greater than two-fold
increase in the PD patient relative to control, and a greater than three-fold increase in the
DLB patient relative to control (Figure 5-1A). Examination of Lamp-2a protein levels by
western blot did not reveal a band at the 72kDa molecular weight at which the protein
was characterized in the mouse brain despite use of four different antibodies (Figure 51B).

Rather, immunoreactivity was detected at an apparent molecular weight of

approximately 50kDa. This represents either a non-specific band or Lamp-2a that has
been deglycosylated due to the prolonged agonal and postmortem time encountered with
human tissue (Figure 5-1B).
Further exploration of the role of Lamp-2a in α-synuclein neurodegeneration
could be accomplished by manipulating the levels of Lamp-2a expression in A53T αsynuclein transgenic mice. Specifically, crossing Lamp-2 knockout mice (Tanaka et al.,
2000) with A53T α-synuclein mice would reveal whether deficiency in Lamp-2a affects
α-synuclein aggregation and disease onset in vivo.

Additionally, this would reveal

whether specific regions are more vulnerable to Lamp-2a knockout compared to other
regions. The expression of other proteins could also be examined to determine whether
other lysosomal or chaperone components are upregulated regionally or ubiquitously in
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response to Lamp-2a knockout. Alternately, region-specific Lamp-2a knockout through
cre-lox recombination or stereotaxic injection of Lamp-2a siRNA to particular brain areas
would reveal the contribution of selective regional deficiencies in Lamp-2a expression in
the development of α-synuclein pathology. This would additionally address the issue of
whether CMA impairment in one region could seed the spread of α-synuclein mediated
aggregation and neurodegeneration to adjoining areas.

Figure 5-1. Increased levels of Lamp-2a mRNA upon the onset of synucleinopathy in
humans. A, Quantitative PCR with a primer against Lamp-2a and a primer against neuron
specific enolase (NSE) as a control was performed on cDNA synthesized from RNA extracted
from the cingulate cortex of a patient with PD, a patient with DLB, or a control patient. Levels of
Lamp-2a mRNA were held relative to the values for the control patient (n=1). B, The cingulate
cortex of a patient with PD, a patient with DLB, or a control patient were analyzed alongside
mouse brain homogenate by SDS-PAGE / western blot for Lamp-2a. Four different Lamp-2
antibodies were used, but an immunoreactive band at a molecular weight corresponding to
glycosylated Lamp-2a (greater than 45kDa) was not able to be identified in the human samples.
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5.3 Lamp-2a found in the brain differs from previously characterized Lamp-2a.
In support of the altered kinetics of Lamp-2a in the brain, this protein has a
different apparent molecular weight than the Lamp-2a found in the liver (Cuervo et al.,
1996; Chapter 2). This most likely results from differential glycosylation. Due to the
important role of glycans in protecting lysosomal proteins from the proteases in the
lysosomal lumen, altered glycosylation may affect the stability of the protein and
potentially explain the functional alterations observed. Further experiments are needed to
fully characterize the differences in the Lamp-2a receptor found in the brain.
Identification of the sites of glycosylation for a protein can be achieved through mass
spectrometry.

Following digestion of the protein with trypsin, the peptides are

deglycosylated with PNGaseF in the presence of O18 water. N-linked glycans are cleaved
from asparagine residues which are consequently converted to O18 aspartic acid. The
resulting mass shift is detectible by mass spectrometry. If the Lamp-2a observed in the
brain is glycosylated on fewer residues than Lamp-2a in the liver, the relevance of this
difference to Lamp-2a stability and CMA function can be examined using site directed
mutagenesis of the glycosylated amino acid in cells.

Alternately, if the differences in

glycosylation between brain and liver Lamp-2a are not found to be due to the number of
sites that are modified but rather in the extent of modification at each site, analysis of the
enzymes in the Golgi apparatus that are involved in glycan modification can be
conducted.
In order to better characterize the role of Lamp-2a in protein degradation in the
brain and other tissues, it is critical to have a reliable marker of Lamp-2a expression.
Currently, neither of the antibodies that are commercially available for Lamp-2a are able
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to recognize the protein without strong signal from a band that is not Lamp-2a (Chapter
2). Because this nonspecific band is at a similar molecular weight to that previously
described for Lamp-2a (96kDa), this potentially confounds the results from the tissues
where Lamp-2a has an apparent molecular weight of 96kDa. It is important to note that,
while the importance of Lamp-2a levels on CMA activity has been supported by
knockdown and overexpression studies that are not dependent on an antibody for
evaluation, extensive characterization of Lamp-2a has been carried out using the antibody
with a non-specific 96kDa band (Invitrogen 51-2200). The antibody was first described
by Cuervo and Dice (1996) in the initial identification of Lamp-2a as a CMA receptor.
Following that, description of the correlation between lysosomal Lamp-2a levels and
CMA activity, Lamp-2a upregulation during starvation and oxidative stress, Lamp-2a
redistribution between the lysosomal membrane and matrix during CMA activation, and
the formation of higher molecular weight Lamp-2a complexes for substrate uptake have
all been documented using that antibody (Cuervo and Dice, J Cell Sci, 2000, Traffic,
2000; Kiffin et al., 2004; Bandyopadhyay, 2008, 2010; Mak et al., 2010). Therefore,
interpretation of some of this data may warrant reevaluation.

5.4

The potential contribution of lipid metabolism to the aggregation of α-

synuclein.
Impaired protein degradation in the brainstem and the spinal cord provides a
mechanism to promote regionally selective protein aggregation. However, it is unclear
how impaired turnover of a multitude of substrates ultimately results in the aggregation
of select proteins. In chapter 3, data suggests that alterations in lipid metabolism are
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present in the regions that develop the most prominent inclusions. Lipids have been
shown to affect α-synuclein aggregation and changes in lipid levels may act as a
modulating factor to promote the formation of α-synuclein oligomers or inclusions as
protein levels rise. Specifically, polyunsaturated fatty acids (PUFAs) have been shown to
promote the formation of α-synuclein multimers (Perrin et al., 2001; Sharron et al., 2003)
while cholesterol lowering compounds decrease α-synuclein aggregation (Bar-On et al.,
2006, 2008; Koob et al., 2010). In chapter 3, decreased levels of ApoE and increased
levels of LDLR were found in the spinal cord relative to the hippocampus. This suggests
that there are decreased levels of lipids in the regions that form more prominent
inclusions in the A53T α-synuclein mice. Further studies are needed to characterize the
changes in lipid metabolism that are occurring and decipher the relationship with αsynuclein aggregation. Levels of various lipids must be measured across brain regions to
determine the specific alterations that are present. Additionally, once the particular lipids
or proteins involved in lipid metabolism are determined, their levels must be manipulated
to decipher a causative role. Increased levels of lipids are found in ob-/ob- mice that lack
the leptin hormone. These mice did not display any changes in Lamp-2a levels compared
to controls. Therefore, lipid levels do not control the expression of Lamp-2a itself.
Because these mice do not express the human A53T α-synuclein, the effect on inclusion
formation could not be investigated. However, manipulating lipid levels in A53T αsynuclein mice through diet or genetic crossing with the ob-/ob- mice would provide
valuable insight into the role of lipids in α-synuclein aggregation. Lamp-2 has been
shown to play a role in cholesterol degradation (Eskelinen et al., 2004; Schneede et al.,
2009). While the spinal cord had decreased levels of lipids and also decreased CMA
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activity, the levels of Lamp-2a are increased in that region. Therefore, it is possible that
Lamp-2a may regulate cholesterol levels in a CMA-independent fashion. Further studies
are needed to examine this possibility.

5.5 Additional lysosomal membrane proteins may potentially contribute to the
direct lysosomal uptake of substrates.
The discovery that direct lysosomal uptake and degradation of substrates is
reduced in the regions that have increased levels of Lamp-2a highlights the need to
reconsider the relationship between Lamp-2a levels and CMA activity. It also suggests
that an additional factor is present in the regions of the brain with lower levels of Lamp2a that promotes increased degradation. In chapter 4, we explored the possibility of an
alternate protein that aids in the direct lysosomal uptake and degradation of CMA
substrates. Our evidence suggests that Lamp-1, a glycosylated lysosomal transmembrane
protein with homology to Lamp-2a, has the potential to serve this function. Previously, it
has been shown that during starvation, levels of Lamp-1 are not upregulated in a way that
corresponds to the increased levels of CMA activity (Cuervo and Dice, J Cell Sci, 2000).
However, the possibility exists that Lamp-2a may serve as a dynamic lysosomal receptor
whose levels change in response to cell stress while Lamp-1 has static expression but is
nevertheless able to mediate the direct lysosomal uptake of substrates. Endogenous basal
levels of Lamp-1 expression may allow one region to have increased CMA activity
relative to another region. Further studies are needed to characterize whether Lamp-1 can
associate with CMA substrates and the Hsc70 receptor.

Co-immunoprecipitation

experiments could be used to determine this relationship.

Additionally, pulldown
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experiments using the twelve amino acid C-terminal region of Lamp-1 could reinforce
whether this sequence can recognize CMA substrates. Additionally, the role of the
KFERQ targeting motif in Lamp-1 binding could be determined using site directed
mutagnesis of known CMA substrates. To determine the functional effect of Lamp-1
expression on CMA activity, overexpression and knockdown studies are necessary to
determine the relationship between levels of Lamp-1 and lysosomal uptake and
degradation.

The additional possibility also remains that other lysosomal proteins are

involved in direct lysosomal uptake and degradation of α-synuclein.

One future

experiment to explore this would involve immunoprecipitation of α-synuclein from
lysosomal extracts. This would be followed by analysis of the proteins that co-eluted
with α-synuclein using mas spectrometry. This method would allow the identification of
possible candidate proteins for direct lysosomal uptake and degradation.

5.6 Concluding remarks
As the second most common neurodegenerative disease and the most prevalent
movement disorder, PD has a tremendous impact on our society. Currently, there is no
cure for PD and treatments are focused solely on alleviating symptoms. In order to
develop an effective therapy, better understanding of the molecular mechanisms
underlying disease is necessary.

While advances have been made in the field of

neurodegeneration towards understanding factors that mediate protein aggregation, many
unresolved issues remain.

Among these is the characteristic aggregation of select

proteins in distinct regions of the brain. Ultimately, comprehensive understanding of the
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pathways underlying this selective vulnerability is necessary to fully understand and treat
neurodegenerative diseases.
Several studies have investigated the therapeutic effects of autophagy induction in
cell and animal models. However, these studies have primarily focused on the bulk
degradation pathway of macroautophagy.

Rapamycin, a compound which activates

macroautophagy through inhibition of the negative regulator of autophapgy mammalian
target of rapamycin (mTOR), promotes clearance of α-synuclein and other aggregateprone proteins in cells (Ravikumar et al., 2002, 2004; Webb et al., 2003). Additionally,
rapamycin has been shown to protect against inclusion formation of tau in drosophila and
of huntingtin in drosophila and mouse models (Ravikumar et al., 2004; Berger et al.,
2006). Lithium, trehalose, and several small molecules have similarly been shown to
clear huntingtin and α-synuclein through induction of autophagy (Sarker et al., 2005,
2007a, 2007b). Autophagy induction has also been accomplished by increasing the
expression of the autophagy-related gene Beclin-1. Lentiviral delivery of Beclin-1 to
cells or mouse models ameliorated the pathology of α-synuclein or amyloid beta
(Pickford et al., 2008; Spencer et al., 2009).

While these findings are promising, they

fail to take into account the selective nature of various neurodegenerative diseases.
Therefore, while this potentially represents a broad-spectrum approach to aiding
clearance of aggregated proteins, it likely is not a targeted therapy capable of addressing
a specific pathology.
A possible therapeutic role for CMA has recently been explored for Huntington’s
disease (Bauer et al., 2010). A peptide that selectively binds the polyglutamine tracts of
mutant huntingtin was fused to the CMA chaperone Hsc70. This construct promoted the
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degradation of huntingtin through CMA and decreased aggregation in a cell and mouse
model (Bauer et al.,2010). It is important to note, however, that CMA is unlikely to be
able to clear pre-formed aggregates. Aggregated α-synuclein has impaired recognition by
Hsc70 (Chapter 4) and cannot be unfolded to pass through the Lamp-2a receptor
(Martinez-Vicente et al., 2008). Therefore, effective use of CMA upregulation as a
therapy must occur early as a protective strategy.
The data presented in this work suggests that there are underlying lysosomal
impairments both in the brain in general and specifically within the regions that are most
vulnerable to developing aggregates. The regions of the brain that develop the most
prominent α-synuclein inclusions have decreased CMA function.

Upregulation of

Lamp-2a levels in the brain is unable to modulate an increase in CMA substrate binding
and degradation.

Further studies are needed to decipher the reasons underlying the

impaired Lamp-2a kinetics in the brain. Targeting this insufficiency provides a possible
therapeutic strategy, allowing the observed upregulation of Lamp-2a to have a functional
impact and serve its intended protective role. Additionally, further investigations are
needed to determine additional lysosomal factors that may promote direct lysosomal
uptake in the regions that develop minimal α-synuclein inclusions. This will provide a
better understanding of α-synuclein turnover and provide an additional possibility of
therapeutic modulation. Finally, understanding of the factors that promote the selective
aggregation of α-synuclein will be crucial in targeting the homeostasis of this specific
protein and in developing a better understanding of the unique pathology observed in PD.
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